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Abstract.  The first primary structure for a nonmuscle 
myosin light chain kinase (nmMLCK) has been deter- 
mined by elucidation of the cDNA sequence encoding 
the protein kinase from chicken embryo fibroblasts, 
and insight into the molecular mechanism of calmodu- 
lin (CAM) recognition and activation has been ob- 
tained by the use of site-specific mutagenesis and sup- 
pressor mutant analysis.  Treatment of chicken and 
mouse fibroblasts with antisense oligodeoxynucleotides 
based on the cDNA sequence results in an apparent 
decrease in MLCK levels, an altered morphology 
reminiscent of that seen in v-src-transformed cells, and 
a possible effect on cell proliferation,  nmMLCK is 
distinct from and larger than  smooth muscle MLCK 
(smMLCK), although their extended DNA sequence 
identity is suggestive of a close genetic relationship 
not found with skeletal muscle MLCK.  The analysis 
of 20 mutant MLCKs indicates that the autoinhibitory 
and CaM recognition activities are centered in distinct 
but functionally coupled amino acid sequences 
(residues  1,068-1,080  and  1,082-1,101,  respectively). 
Analysis of enzyme chimeras,  random mutations,  in- 
verted sequences, and point mutations in the 
1,082-1,101  region demonstrates its functional impor- 
tance for CaM recognition but not autoinhibition.  In 
contrast,  certain mutations in the  1,068-1,080  region 
result in a constitutively active MLCK that still  binds 
CaM.  These results suggest that CaM/protein kinase 
complexes use similar structural themes to transduce 
calcium signals into selective biological responses, 
demonstrate a direct link between nmMLCK and non- 
muscle cell function, and provide a  firm basis for 
genetic studies and analyses of how nmMLCK is in- 
volved in development and cell proliferation. 
T 
HE  effects  of changes  in  intracellular  free  calcium 
levels  on  nonmuscle  cell  motility,  organelle  move- 
ment, and cell morphology (2,  10, 20, 21, 35, 45, 53, 
55, 81, 82) appear to involve, in part, the activation  of the 
calmodulin/myosin  light chain kinase (CaM/MLCK) ~  com- 
plex (3, 8, 10, 16, 17, 30, 35, 45, 55, 82, 84) which catalyzes 
the stoichiometric phosphorylation of myosin light chains at 
specific  sites (8,  29,  77).  However,  our knowledge  about 
CaM/MLCK signal  transduction  complexes,  how they are 
properly assembled, and how these supramolecular struc- 
tures are able to selectively transduce calcium  signals  into 
cellular responses in nonmuscle cells is incomplete.  For ex- 
ample,  the primary structure for a nmMLCK has not been 
described for any phylogenetic  species.  Relatedly,  it is not 
known which  features  of nmMLCK  are important  in the 
proper recognition  of CaM,  such  that a  functional  CaM/ 
MLCK complex can be formed during the time constraints 
1. Abbreviations used in this paper: CaM, calmodulin; CEF, chick embryo 
fibroblast; MLCK, myosin light chain kinase; nm, nonmuscle; r, recom- 
binant; sk,  skeletal muscle;  sm, smooth muscle. 
of cellular responses.  This knowledge is needed for a com- 
plete interpretation  of experiments  that seek to explore the 
possible in vivo roles of CaM/MLCK signal  transduction 
complexes in nonmuscle cell responses.  On a more general 
level, knowledge about the specific features of CaM/enzyme 
recognition  and insight into how CaM activates an enzyme 
are key to understanding  how intracellular  calcium signals 
are selectively  transduced into discrete cellular  responses, 
predicting how mutations or other perturbations of CaM/en- 
zyme complexes might alter cellular responses to environ- 
mental stimuli, and facilitating attempts at targeted drug de- 
sign based on selective structural  and mechanistic  features. 
There are at least three forms of MLCK found among ani- 
mal tissues: skeletal muscle MLCK (skMLCK), smooth mus- 
cle MLCK (smMLCK) and nonmuscle MLCK (nmMLCK) 
(for a  review see reference 72).  The  skMLCK has  been 
shown (32, 33, 66, 73) to be biochemically,  genetically, and 
physiologically  distinct from smMLCK and nmMLCK. For 
example, the similarity between the amino acid sequence for 
smMLCK (23, 48, 50, 60) and that for skMLCK (33, 66, 73) 
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and other CaM regulated protein kinases (5, 7,  11,  12,  15, 
26, 46, 64). In terms of cellular physiology (for a review see 
reference 72), the smMLCK and nmMLCK are thought to 
be involved in the initiation of contraction in response to cal- 
cium signals, whereas this role is fulfilled by the troponin 
complex in skeletal muscle tissue. While the smMLCK and 
nmMLCK are similar to each other in mobility during SDS- 
PAGE and immunoreactivity (9, 17, 75), it is not known how 
they are related structurally or genetically. 
Clearly, there is a need to define in more detail the molecu- 
lar constituents of the nonmuscle motility systems. As an ini- 
tial step towards filling this void in our knowledge, we report 
here the amino acid sequence of a nmMLCK (deduced from 
the eDNA sequence encoding the chicken embryo fibroblast 
protein),  and the  relationship of its primary  structure to 
other  CaM  regulated  protein  kinases,  especially  MLCK 
from muscle tissues. 
Our knowledge of the primary structure of a nmMLCK, 
and the insight provided by our demonstration that the cata- 
lytic and CaM regulatory regions of nmMLCK and smMLCK 
are identical in amino acid sequence, allowed us to use the 
information gained from previous studies (19, 23, 48, 50, 78) 
of smMLCK to directly test, by site-specific mutagenesis, 
models (4,  27,  33,  39, 42-44,  48,  50,  61) of how MLCK 
structure might correlate with CaM binding and enzyme ac- 
tivation. All of the models have in common the assumption 
that there are key regions within the MLCK sequence that 
prevent the manifestation of protein kinase activity due to an 
intramolecular inhibition, or autoinhibition, and that activa- 
tion by CaM results from the release of this intramolecular 
inhibition. The models differ in whether or not they assume 
that the CaM binding sequences are overlapping (4, 27, 33, 
42, 44, 61), or distinct (39, 50) from the autoinhibitory se- 
quences. The most popular of these models for MLCK is the 
pseudosubstrate hypothesis (4, 27, 33, 42, 44, 61). A more 
detailed version of this hypothesis postulates that a portion 
of the CaM binding sequence, that has some similarity to the 
myosin light chain substrate, is the most critical region for 
maintaining autoinhibition (61). However, the results of ini- 
tial deletion mutagenesis (4, 33) and recent proteolysis (39) 
studies of MLCK are not entirely consistent with the models 
for MLCK that equate the CaM binding sequences with au- 
toinhibitory activity. Therefore, the lack of agreement be- 
tween initial site-specific mutagenesis results and models of 
how the primary structure of MLCK is related to CaM bind- 
ing and relief of autoinhibition, combined with previous 
differences among models, require a reappraisal of some of 
the fundamental assumptions upon which these models are 
based. 
We have used the eDNA sequence of nmMLCK described 
in this report to test, through the use of site-specific muta- 
genesis, extant models about CaM recognition and relief of 
autoinhibition of MLCKs. The results,  which include the 
production of a novel conformational suppressor mutation in 
the CaM binding sequence, are consistent with the hypothe- 
sis that the 20-residue CaM binding segment of smMLCK 
and nmMLCK, originally identified by chemical fragmenta- 
tion and synthetic peptide analogue studies (48, 50), is quan- 
titatively important in MLCK's selective recognition of and 
response  to  CaM.  Relatedly, the data allow the tentative 
identification within the MLCK sequence of a CaM regula- 
tory unit, which includes a new definition of the autoinhibi- 
tory region. The correlation of  these structures with function 
and molecular mechanism has, in turn, been used as the ba- 
sis for an initial examination of how nmMLCK might be in- 
volved in cell function through the use of antisense oligode- 
oxynucleotides on fibroblasts. 
Materials and Methods 
Protein Cleavage, Peptide Isolation, and Amino Acid 
Sequence Analysis 
Proteolytic digestion of chicken gizzard MLCK was carried out using previ- 
ously described protocols (48,  68). The peptides were isolated by HPLC 
(48, 68) over a Brownlee RP8 (1.0  ×  250 mm) column (Brownlee Labs, 
Santa Clara,  CA)  using 0.1%  trifluoroacetic  acid  (solvent A) and 60% 
acetonitrile containing 0.08 % trifluoroacetic acid (solvent B). 
Amino acid composition analyses were done on acid hydrolysates (6 N 
HCI, 20-24 h) using the Picotag (Waters Associates, Milford, MA) proce- 
dure modified as previously described (68).  Automated Edman degrada- 
tions were performed on a protein sequencer (model 470A; Applied Bio- 
systems Inc.,  Foster City,  CA) and PTH amino acids were identified by 
HPLC  with an on-line PTH  analyzer (model  120A; Applied Biosystems 
Inc.)  according  to the  manufacturer's  recommended  and previously  de- 
scribed (68) protocols. 
DNA Sequence Analysis 
DNA sequences were obtained by using the protocols described in detail 
by Zimmer et al. (85). Briefly, DNA sequencing reactions were performed 
using a Biomek  1000 pipetting workstation (Beckman Instruments, Inc., 
Palo Alto, CA),  commercially available fluorescent-labeled primers, and 
the  dideoxynucleotide  chain  termination  method  (67)  according  to  the 
manufacturer's  (Applied  Biosystems  Inc.)  recommended  protocol.  The 
fluorescent-labeled reaction products were analyzed on a model 3703, DNA 
sequencer (Applied Biosystems Inc.) (13). Isotopic manual sequence using 
deoxyadenosine  5'lc~-35Slthiotriphosphate  (>600  Ci/mmol;  Amersham 
Corp., Arlington Heights, IL) was obtained with the Sequenase protocol 
(US Biochemical Corp.,  Cleveland, OH).  Where necessary, exact-match 
synthetic oligodeoxynucleotide primers, made on model 380 and 381 DNA 
synthesizers (Applied Biosystems Inc.), were used in the manual, isotopic 
protocol. 
Construction and Screening of a Chicken 
Embryo Fibroblast cDNA Library 
Total cytoplasmic RNA was isolated from secondary cultures of chicken 
embryo fibroblast (CEF)  cells (74) using the phenol/SDS extraction pro- 
tocol (70). Poly(A)+RNA was selected from the total cytoplasmic RNA by 
two passages over oligo=dT-cellulose (70). A 3,gtll eDNA library contain- 
ing '~1.1  x  106 PFU was prepared commercially  (Clontech Corp.,  San 
Diego,  CA) by the method of Huynh et al.  (38). 
The approach used for screening and characterization of positive clones 
was the same as that previously described by Zimmer et al. (85). Briefly, 
two library equivalents were screened by hybridization with a 32p-labeled 
fragment (bases 2,218-2,785; Fig. 2) isolated from a partial MLCK eDNA 
clone (50).  DNA  from positive clones were characterized by restriction 
mapping or DNA sequence analysis. Two large inserts, M1 and h50, were 
obtained from this screening. These were indistinguishable by restriction 
mapping and DNA sequence analysis. A fragment consisting of 400 bp of 
the most 5' end of clone M 1 (Fig. 1 A) was used to rescreen the same library, 
resulting in the isolation of two additional clones (~X23 and ~6; Fig.  1 A). 
These three overlapping clones were used to establish the complete DNA 
sequence of the region encoding fibroblast MLCK. 
Strategy for Establishing DNA Sequence of 
MLCK cDNA 
The strategy for establishing the DNA sequence was essentially the same 
as that used previously for CaM genes (85) and is outlined in Fig.  1 B. 
Briefly,  the  inserts  of  clone  X23  and  ~6  were  subcloned  directly  into 
Bluescript II and the fragments for sequencing were obtained by nested de- 
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son, WI). In addition,  three overlapping clones were subdigested with re- 
striction endonucleeses as indicated in Fig.  1 B and subcloned into one of 
the following vectors:  M13mp8, M13mp9, M13mplt, or Ml3mpl9 (New 
England Biolabs, Beverly, MA); Phagescript (Stratagene, La Jolla, CA); or 
Bluescript H (Stratagene). These plasmids were transformed into competent 
Escherichia coli (strain UT481 or the XLl-blue strain in the case of Blue- 
script II). Single- and double-stranded DNA templates were prepared from 
the transformed bacteria essentially as described (54). Sequence data were 
assembled and analyzed using the PC Gene and IG-Suite software packages 
(Intelligenetics,  Mountain  View, CA). 
Preparation of  Recombinant DNA Encoded Proteins 
The construction and verification of structure for the Eg4K and EI20K mu- 
tant CaMs followed previously described protocols (14, 65, 80). A caltrac- 
tin cDNA (36) in the expression vector pKK223-3 was obtained from Dr. 
Bessie  Huang,  Research  Institute  of  Scripps  Clinic  (La  Jolla,  CA). 
Calmodulin and caitractin were purified essentially as described  (37, 80). 
Briefly, phenyl-Sepharose (Pharmacia Inc.,  Piscataway, NJ) chromatogra- 
phy was used to adsorb proteins in buffer A (50 mM Tris-HCl, pH 7.5) con- 
taining  1 mM 2-mercaptoethanol,  500  mM NaCI,  0.3  mM CaCh.  The 
column was washed with the same buffer, then the bound proteins eluted 
by changing to buffer A containing  1 mM EGTA and 0.5 mM DTT. 
rMLCKI encompasses nucleotides 2,220--4,012 (Fig. 2) of the fibroblast 
MLCK cDNA.  The amino  acid  sequence  of rMLCKI  minus  the four 
amino-terminal linker amino acids is given in the top line of Fig. 3. To ligate 
the coding region of rMLCK1 into the expression vector pVUCH1 (49, 50) 
and maintain the appropriate spacing from translational elements in the ex- 
pression vector, as well as maintain the reading frame, an 1  l-bp synthetic 
oligodeoxynucleotide adapter encoding four additional amino acids (Ala- 
Asn-Ser-Gly)  at the amino  terminus  was used.  A  site-specific, cassette- 
based mutagenesis approach (14) was used to generate the 20 mutant con- 
structs shown in Fig. 5. All mutations were verified by restriction mapping 
and DNA sequence analysis across the mutated region. 
rMLCKI and mutant derivatives of rMLCK1 were produced in E. cell 
and purified by the protocols described below. UT481 E. coli cells, trans- 
formed with expression plasmids,  were grown in NZCYM medium until 
they reached an ODss0 of 0.5-0.7. Protein expression was induced by the 
addition of IPTG to a final concentration of 0.5 mM. Ceils were cultivated 
for an additional hour, harvested, and either processed immediately or fro- 
zen at -20°C until needed. The purification protocol consisted of the fol- 
lowing six steps. 
A  C 
..  Bg 
9, 
)vll 
200 bp 
® 
i  ~6A-B 
B 
Bg  Bx 
I  I  I  ~I  .~J  I  v,  ~- 
'  I ~'~  I 
200 bp 
Figure 1.  The complete coding sequence for CEF MLCK has been determined by analysis of overlapping cDNA clones.  (A) Restriction 
maps of DNA isolated from the bacteriophage exhibiting hybridization with fragments isolated from a partial MLCK cDNA (50) are shown. 
Only the segment containing the inserted cDNA molecules is diagrammed.  Names of clones refer to the particular filter upon which the 
bacteriophage were isolated. The placement of the restriction sites was accomplished by analysis of restriction enzyme digests, as described 
in Materials and Methods.  Overlap of individual clones was established by DNA sequence analysis.  The heavy bars represent the open 
reading frame. The circled E  indicates the location of the Eco RI sites generated as part of the linker during library construction.  (B) 
The strategy used to establish the complete DNA sequence of the 3,774-bp open reading frame and 698-bp flanking DNA is shown. Only 
the minimal data necessary to establish the complete DNA sequence are shown, although additional confirmatory sequence was obtained. 
Sequences were obtained by using the dideoxy chain termination method (67) and universal primers, except where indicated by filled circles. 
Filled circles indicate sequences obtained with exact match oligodeoxynucleotide primers. Arrows with vertical bars indicate selected sub- 
cloned fragments.  Plain arrows indicate clones from nested deletion experiments.  Abbreviations used for restriction endonucleases are 
Bg, Bgl II; Bx,  Bst XI; Hc;  Hinc II; P, Pst I; R, Rsa I; S,  Sac I; and X, Xba I. 
Shoemaker et al. Nonmuscle Myosin Light  Chain Kinase  1109 t ccccngtt t gagagccocccacagaocct  ggaagcst  cagaao￿acaggagat  t aaatt ca  agagcsssgtt  tc~gggsaaccasaaccagat  96  goagtggt  tcssagao￿gtgtacctat  t saaactgga￿aa  135 
ggt  a t tcaaat t t st  gsagaaga  t got  sct  cat  tgct  tat  o￿t  t sa~gaaa~cct 6cct  g~Jg9gacsgt  o￿at  ct t acagct  gt  go&get t tcsacccca9ao￿ccasac  t t ecaccagct006 t gt t sac t gLcaasaggcc  279 
tsss~ttgaa~a~9t~ctccat~cttttccs~t~tctt~asa~s~gcact9%9agt~aao9gcaa~sctLt~tgctgca~t9ctst~tag9mo9t~tscct~t~ct~arJstcacst~gcttctcsat~aacsacc~ttc  422 
sgt  st  gcccat  tccact t t ¢9aagc6gga￿t  t gcsss~ct￿act  966caagatgcct  t gccagaagatgatggcat  t t ataclt 6tctggctgasaacut9csg6scgggcatcst gcagtgct  cso￿t  cacsgtcusgaa  565 
sa•aa•agca••ss0aagg•a0asrJ•ta•a•aggctgccasattsaaacsaga¢tttt0•s••cat•ttcct•saaggg•t•s•tgacct•esa•ts  ATG 6AT GGA AGT CkA GTG 6TA ATG A61 5T5 ~AA  696 
Asp 61y  Ser  Gln 931  lie Net  Thr 1,31 61u 
GTA TCA GCT  AAC CCA TGT  6CT GAA ATT ATC TC16 CT6 CAC AAT GGG ~  ~  ATC GAG GAG ACA ~U~ GAT TTT  CAC TTT  GAG AA6 ~  GSC ~T  GAA TAG AGI" CTG  TAC  803 
11  1,al  Ser  A1~  Ass  Pro  6ys  Pro  61u  lie  lie  Trp  leu  HIS Ass  Gly LY~ Glu  Ile 61n  61u  Thr  51u  Asp  Phe HIS  Phe 6lu  Lys  Lys  Gly Asn 61u  Tyr  Ser  Leu  TF 
AIC  ~66  GAA GTA TTT  CCT 6AA GAG AGA GGC ~  TAC ACC TG1, ~  GOC T66 AAT Cd~A TI"A 6616 GAP.  ACT GAA ACA CAG GCT ACA TT6 ACA ~TG CAA GAG CCT CArl KAT  911 
47  ]le  Gln Glu  1,al Phe  Pro  Glu  Asp Thr  Gly lys  lyr  Thr Cys 61u  Als  Trp Ass  Glu  Leu Gly Glu  Thr  Gln Thr  Gln  AIs Thr  teu  Thr  1,al 61n  Glu  Pro  Gln Asp 
C~C 6TT  GAG CCG TG~  TTC  ATT AGC /~A CCG AGA TCA GTG ACA GCA C¢T GCT ~  CAA ~AT  6TC CTT  ATA TCT  T&T  ECC ATT 6CT C~A GAT CCT  TTC CO6 ACC BTT  GAG  1019 
83  ~ly  lie  Gln  Pro Trp  Phe  lie  Ser  Ly$  Pro  Aro Set 1,el Thr Ala Ale Ala Gly 61n  ksn 1,al leu  Ile Set Cys All  Ile Ale Gly Asp Pro  Phe Pro Thr  1,a1 HI~ 
TG6 TTT  AAA GAT GGG CAA GAA ATA ACA CCA GGA ACA GGC TGT  GAA AT6 CTG C~  AAT GAA CAT ATC TTC  ACA CTG ATC TT6 AGG PAT GTA GAG TCT  CGT CAT GGA GC~  1127 
H9  Trp  Phe  Lys  Asp Gly Gln 51u  Ile  Thr  Pro  C~]y Thr  Gly Cys 01u  lle  Leu Gln Asn Elu 6sp  Ile  Phe Thr  Leu  Ile  Leu At9 Ass Val  61n  Ser  Arg His Ala Gly 
CAA TAT  GAA ATT GAG CTC A6G AAC GAA GTT  ~  GAA Tr.,C AGC TGC CA6 BTG TCT  CTG AT6 CTG CGA GAG A6T 1'CA GCI T£C AGA ~A GAA ATG CTC AGA GAT BC,-G A~  1235 
155  Gin  Tyr  Glu  tle 51.  Leu Arg Asn Gin 1,ai 61y 61u Cys  Sen Cys Gin Val  Ser  Leu Net  Leu Arg 61u  5er Set  A1a 5er Arg A1a G1u Net  Leu Ar9 Asp Gly Arg 
6AA T6A 666 AGC TCI GGA C166 CGA AC~ CAT OGT  GGA AAT TAT  CIGT ECA CTA ACA TTT  ~T  AGA ACA AGT  GGC TTC  AAA GAG AGC AGC AGT 6AA ACC AGA GCA 5CT  GAG  1343 
191  Glu Set Ale  Ser Set 61y  Glu Arg Arg Asp Gly Gly Ass  Tyr 61y Ala  Leu  Thr  Phe Gly Arg Thr  Set Gly  Phe lys  Lys  Ser  Ser Ser  Glu Thr  Ar  0  Aln Ala  Glu 
GAA GAG CAG GAA GAG GTC  CGA CI(~C 5TA CTG AA5 kGG CGA GT~  GkA ACT CGG GAA CAC ACA GAG GAG 6GC CTG  AGG GAG GAG ~  GCT  GAA Ck~ CTT  GAT  TTC  CGT  GAG  1451 
~27  GlU Glu Gln 61u  Asp Val  Ar  9  61y 1'sl  Leu Lys  Arg Arg Val  Glu  Thr Arg Glu  His  Thr  Glu 61u  Set  Leu Arg Gln 61n  Glu  Ala Glu Gln  Leu Asp Phe Arg Asp 
AT'F TTA 6GC AAG AAA GIG AEC ACC ~  AGT TTT  TCT  GA~ GAG CAT CTG A/~ EAA ATC CCA GEC GA~ CAA ATE C~C  TTC  EGA GCA GAC CT& CAG CGG CAB GIG AAA CCC  1559 
~63  lie  Leu Gly  Lys Lys  ¥sl  Ser  Thr  Lys  Set  Phe Ser  Glu Glu Asp  Leu  Lys  Elu  Ile  Pro A~a Glu Eln Net  Asp  Phe Ar9 Ala 6sn  Leu 61n  Ar9 Gln  Val  Lys  Pro 
AA& ACC TTG  TCA GAG GAG GAA AGG AAA GTT  CAT C.-CT CCT  CAG 666  GTG GAG TTC  CGC TCC GIG CTG GCE GAG AAA 6GC ACC CCA AAG ACC CCA CTG CCA GAG AA6 GTG  1667 
290  Lys  Thr  Leu  5e£ 61u  E~u Glu Arg Lys  Val  Hts Ala  Pro  Gln Gln  1,s1 Asp  Phe Arg Set 1,a1 Leu Ale  Lys  Lys  Gly Thr  Pro  Lys  lhr  Pro  Le~  Pro Glu  Lys  1,31 
CEA C6T  CCT  AAG C6A GCC GTT  ACA CAT TTC  AGA TCT  GTG CTG GC,  C GCA AAG AA6 AAG CCC CCT 6CA GAE KP.T GGC AGC ECT AGC ACC CCA GCA CGA AAT GCC CGT GCC  171'5 
335  Pro  Pro P¢o  Cys  Pro  Ala  1'al  Thr  Asp Phe Arg Ser  Val  Ceu Gly Ala  Lys  lys  Lys  Pro  Pro  Ala GIu Asn Ely  Ser 61a  See Thr  Pro  Ala P~ Ass  Ala  Arg Ale 
GGT  T6T  6/~ GCA GAG AAT 6CC ACC CCC AAT TET  GAA GCC CCT GCT CCC A/~ CC6 GTA GTE AAk AAA GAA GAG AAG AAT GAG AGG ~  TGT  GAA CAT 6£~  TGT  6CA GTG  1883 
371  G]y  5er 61U Ala Gln Asn Ala  Thr  Pro Asn  $er Glu AIa Pro Ala  Pro Lys  Pro  1,a1 Val  Lys  Lys  61u  Glu  Lys  Ass Asp Arg Lys  Cys Glu Hi~  Gly Cy$ Ala 1'a1 
GTG GAT GGA GGA ATA ATT GGG ~  ~  GCT  GAA AAC ~  CCA GCA GCA 6GC AA6 CCA ACA 6CA CCA EEA AGC M~A GGA ACA GCA CCA TCC TTT  ACA GAG AAG CTT  GAG  1991 
407  1,31 Asp Gly Gly  11o  Tie  Gly Lys Ly$  A]a Glu Ass  Lys  Pro  Ala ATe  Set  Lys  Pro  Thr  Pro  Pro  Pro Ser  Lys  Gly Thr  Ala  P~  Ser  Phe Thr  Glu Lys  Leu EIn 
GAT GCT AAA GTA C-CA GAT GGT GAA ~  TTG  ~TC  TT6 6AA TGT  CGA ATT  TCC TCT  CAT CCC CCT C-CA TCT  GTC  AGC TGG ACT CTA GAG AGC ~  GC6 ATC AAA ;CA TCC  2O99 
443  Asp A1a  Cy3  Val  A1a Asp Gly 51u  Lys  Leu 1,al Leu Gln  Cys Arg  lie  5er  5er Asp Pro  Pro kin  Ser Val  Ser  [rp Thr  Leu Asp Set lys A1a  lie Lys Ser  5e£ 
#.AG TCC ATT GTC ATC TCC CAA ~A  ~A  ACA CT~ TGT TCA CTA .~66  ATT GAG ~6  GTC ATG 6CA ~  6+~,T  ~  ~  ~  TAC ~  TGC AT6 GC6 GAG ,~,61  GCA GGA 5GA  2207 
479  ly~  5er  [Xe Val  lie  Set  Gin  Glu G~y  Thr  Leo Cys 3er leu  Thr  lie 01u  Lys  Val  Net  Pro  Gtu  A~p Gty ~ly  Glu Iyr  Ly$ Cys  lie  Ala  51u Ass Ala Ala Gly 
AAA 6CA GAA TGT  GCT  TGC AAA GIG CTT  GTG GAA GAT AC6 TCA TC6 ACA AA6 6CT  GCG AAG CCA GCT GA6 ~  AAG ACC AAG AJ~6 CCT AkG ACC ACA CTT  CCC CCT  5TG  2315 
515  Ly~  Ala  G]u  Cys  Ala  Cys  tys  VaT  Leu Val  61~ Asp  Thr  3er 3er Thr  lys  61a Ma  lys  Pro  Ale Glu ly$  Lys  Thr  Lys lys  Pro  Lys  Thr  Thr  Le~  Pro Pro  Val 
CTG  TCA A6A GAA AGC AGT GAA 566  ACA GTG AA5 AAG AAA 6CA GCT CCA AAG ACT CCT CCA AAA GCA GCT ACI  CCC CCT GAG ATC ACT GAG TTC  CCA GAA GAC A&A AJ~  2423 
551  Leu  Ser  Thr  Glu  Set  Ser  Glu Ale  Thr  Val  Lys  lys  tys  Pro  Ala  Pro tys  The  Pro  Pro  lys Ala Ala  The  Pro  Pro  Gln  ]le  Thr  Gln  Phe  Pro  61u  As9 Arg Ly$ 
GTC  C~T  GCT  GGT ~AA TCA GTG GAA TTG  TTT  GCC GAk GTG GTA GGA ACA 6CA CCC ATA ACT 1GC ACC 16G ATO AAA TTC CGT AA~ GAG ATT CAA GAA ~1  G/LA TAT  ATC  Z531 
587  Val  Arg Ma  01y  Glu  See  ¥al  film Leu  Phe Ala  Lys  Val  V~l  61y  Thr  Ala  Pro  lie  Thr  Cys  Thr  Trp  i4et  Lys  Phe Arg Lys  Gln  Ile Gln Glu As~ Glu  Tyr  lie 
AAA ATT  GAG AAT GCT GAA AAC AGC ACC AAG CTA ACA ATA YCA TCG ACA /~G  CAB GAA CAC TGC GGA TGT  TAC AC6 CTA GTT  GTA GAA AA6 A/~ C]T  5GC AC-C AGA CAA  2639 
623  Lys  lie  Glu  Asn  Ala G]u  Asn 3er  Ser  Lys  Leu  Thr  Ile  Set 3er  Thr  Lys  Gin  Glu His Cys Ely  Cy$ Tyr  Thr  Leu Va)  ¥a1  G]u  Ass  Lys  leu  Gly 3er k¢  6  Gin 
OCA CAA GT6  AAC CTT  ACA GTl  GTT  GAT ~  CGA GAC CCA C£T CCT  GGA ACG CC1  TGT  GCA TCA GAG ATA CGG AGT TCT  TCC CTC ACT C1~  TCA T~G  TAC GGC TCC  TCT  2747 
659  A]a Gin Val  Asn  Leu  Thr  Val  VaT  Asp  Lys  Pro Asp Pro Pro  Ala Gly Thr  Pro  Cys Ala  5er Asp  Ile Arg 5er 5er  See  leu  Thr  leu  Ser  Trp  Tyr  Gly 5er  Set 
TAT  GAT  GGT  GGA AGT  GCG GTG  CAG TCC  TAG ACT  GT6 GA£~ ATC  TC-G AAC TC6  GTG  CAT AAC ~  TGG  ACA GAG CTC  ACT ACE TGC  CGC AGC AC& TCT  TTC  #.AC GTG GAG  2655 
655  Tyr  Asp Gly Gly  Ser  Ala  Val  Gin  Set  Tyr  Thr  Val  61u  Ile Trp Asn Set Val  Asp Ass  L~s  Trp  Thr  Asp Leu  Thr  Thr  Cys Arg 5er  Thr  Ser  Phe Asn Val  Gin 
GA6 CTG  GAG GCT  GAC CGG GAG TAG AAA TIC CGT  GTA CGA GCT  GCT  AAC GTG  TAC GGC AIC AGT GAB CCC AGT  CAA GAA TCT  GAG GTG GTA AAA GTT  GGA GAG AAA CAA  2063 
731  Asp Leu  Gin Ale  Asp Arg Glu  Tyr  Lys  Phe Arg Val  Arg Ale  A1a Asn Val  Tyr  Gly  [le  5er 61u  Pro Set Gin Glu 5er Gl~ Val  Val  lys  Val  Gly G1u  Lys 61n 
GAA GA-  a, GAA CTT  AAA GAG GAG GAA GCA GAG CTG  TCT  GAG GAT GAA GGC AA~ 6~A ACA GAG GTC  AAC TAT  CGG ACA GTT  ACT ArC AAC ACC GAA CAG AAA GTT  TCA GAT  3071 
767  Gtu  61u  61u  Leu  Lys  Glu Glu Glu  Ale Glu  Leu 3er Asp Asp Glu G1y Cys Glu  Thr  Glu VeI  Ass  Tyr  Arg Thr  Val  Thr  [le Ass  Thr  Glu Gln  Lys  Val  5er Asp 
GTC  TAT  ~61  ATT  GAA GAA AGA CTG  GGA TGG  GGG AAA TIT  GGA CAJ~ GTC  TIT  AGG CTI  GTT  GAA /tAG AAG ACT  GGA AAA GIG TGG  C-CA GGA AAA TIT  TTC  AAA GCA TAT  3179 
803  Yel  Tyr  Ass  Ile  51u  Glu Arg Leu Gly  Set Gly lys  Phe Gly Gin V&l  Phe Arg Leu  Val  Glu  lys  Ly$  Thr  Gly tys  Val  Trp  Ala Gly  Lys  9he  PPe Lys  Ale  Tyr 
TCT  GCA AAG GAA AAA GAG AAC ATA AfiG GAT  GAA ATC AEC ATC ATG AAC TGT  CTG  CAT CAC CCA /LAG CT6  GIG CAA TGT  GTA GAT GCC TTT  Cd~A GAA ~  GCC AAC ATT  3267 
830  Ser  Ala  lys  Glu  Lys  Glu  Ass  lie  Arg Asp Glu  Ile  5er  ]le Ket  Asn Cy~  Leu His  His  Pro  Lys  Leu ¥al  Gin Cys  Val  Asp Ale  Phe Glu Glu  Lys  Ala Asn  Ile 
GTT  AT5  GTC  TTG  C~LA AT5 GTT  rCT  GGA GGA C~kA CTC  TTT  GAA CGT  ATC ATT  GAT  GAA GAC TTT  CAA CT6 ACA GAG AG6 GAA TOC ATT  AAA TAT  6TG  AGG GAG ATT  TCA  3395 
875  Val  Net  Yal  Leu  G1u Met  Vel  5er  Gly Gly Glu  Leu  Phe Glu Arg  lie  lie Asp G1u Asp Phe 61u  Le~ Thr 61u Ar  9 G1u Cys  lie  Lys  Tyr Net Arg G1n  lle  5er 
•  C~ GGA 51T  GAG TAC AT6 CAT  AAG GAG GGI ATr  GTC  CAT  TTG  GAT  TTG  AA5 CGA C-AA  AAT ATI AT6 TGT  GIG AAC ~.AG ACT  6GT  ACA AGT ATC AAA CTC  ATT  CAC  TTC  3503 
911  Glu Gly Val  51u  Tyr  Ile  His  Lys  Gin Gly  lie  Va}  His  teu  Asp  Leu  Lys  Pro  Glu Ass  [le  Met Cy$ Val  Ass  Ly~  Thr  Gly Thr  Ser  Ile  Lys  leu  []e Asp  Phe 
GGA CTT  GCA AGA AGA TTA  GAA AGC GCA GGT  TCT  CTC ~  GIT  CTC  lIT GGG ACA CGT  BAG TTT  GIG GCT  CCA GAA GTT  ATA AAC rAT GAA CCT  ATC  GGA TAT  GAA /,CA  3511 
947  Gly  Leu AIa Ar  9  Arg Leu  ~lu  Ser Ala  Gly 3er  Leu  Lys  Val  Leu  Phe 51y  Thr  P£o GIu  Phe ¥a1  Ala  Pro  Glu  Va~  lie Ass  Tyr  Glu  Pro  lie  Gly lyr  G]q  Thr 
GAT  ATG  rGG AGT ATA GGA GTT  ATC  TGC  TAG Arc CTG GTC  AGT  GGG CTT  TCT  CCC  TTC  ATG GGA GAC AAC GAC AAC 6AG ACE CTG  GCC  AAT GIG ACC  Tcr  GCC ACG TGG  3719 
983  Asp Met  Trp  5er  lie G1y  VallSe Cys  Tyr  lle  Leu ¥ai  5er Gly  Leu Ser  Pro Phe Met  Gly Asp Ass Asp Ass GIu lhr  Leu AIa Ass VaI  Thr  Set AIa  Thr  Trp 
C,J~C TTC  CAT GAT GAG GeT TTT  GAT 6/~A ATC TCT  GAT GAT C-CC ~  GAC TTT  AT6 AGe A/,T CT6 616  AAG AAA 6AC ATG A/~ AGT CGC IIA /~T  TGT  ACT CAA TGT  CTT  3627 
1019  Asp  Phe Asp Asp Glu Ale Phe Asp Glu  I~e 5er Asp Asp Ala Lys  Asp Phe  [le  Ser  Ass  Leu L~  lys  Ly$  Asp Hot  lys  Set Arg Leu Ass  Cy$ Thr  Gin Cys  Leu 
CA6 CAC CCG T66 CT5 CAk AAA GAG ACC AAA AAC AT5 GAA CCC k~A AAA CTT  TCC AAA GkT AGG ATG Ak6 ~  TAT AT6 GCC AGA AGA GAA TGG GAG AAA ACA GGC CAT  3933 
1055  Gin His  Pro Trp  Leu Gln lys  AS  9  Thr  tys  Ass  Ret  6lu  Ale  Lys  Lye  Leu Ser  Lys  AS9 At9 14st Lys  Lyre Tyr  Net  Ala Ar6 Arg Lys  Trp Gln  Lys  Thr  Gly H~s 
6CT 616  C6A GGA ATA CIGA  AGA CTG TCA TCC ATG 6CA ATG ATT TC? C~T  AT6 A6T 666 AC~ GAG GC6 TCT  666  AGC TC~ 6CT ACC AGC CCG ATA AAT GCA GAG AGA GTA  4043 
1091  Ale  Val  Arg Ala  Ile 61y  Arg Leu 5er Ser  Net  618 Het  ]le Set Gly Net  Set 51y  Ar6 L1s Ala  5or Gly Set Set Pro Thr  Ser  Pro  Ile Asn Ala Asp Lys  Val 
GAG kAC rd~ GAT 5CC TT6  CTT  C~  GAA GT6 GCT GAG C~A kA6 CCC CAT GTA AA6 CCA TAC TTT ACT FOG AGA 6TC  CTT  GAC ATG GA6 611  GTG GAA C156 A6T 6CT  ~;r  4151 
1127  61u  Asn ~lu  Asp  Ala  Fhe Leu Glu 6iu  Vol  Ale  51u Glu  L¥S  Pro  HIS Val  Lys  Pro  Tyr  PFe The  Lys  Thr  lie  Leu Asp Net 61u  Vel  Val  Glu Gly  Ser  Ala Ala 
AGG TTT  C,  AC TGC A/~ 6TC C~A GGC TAT  CCT GAG CCT 6/~  GTk ATG TGG TAC AAk CAT 6AT CAG CCT GTC  AAG GAG TC6 CGT CAC TTC  GAG ATA EAT T6T  GAT ~  6AA  4259 
1153  A¢  6  Phe Asp  Cys  Lys  Ile Glu Gly Tyr  Pro  Asp  Pro  61u  Val  Nat  Trp  TyP  Lys  Asp 6sp  GI~  Pro Val  Lys  GIU Set  Arg His  Phe  Gin  Ile ksp  Tyr  Asp Glu Glu 
GGG AAC TGT  TCT  TTG  ACl  ATT  TCT  GAA 5TA TGT  G66 GAG GAT GAT GCC AJ~ TAC ACC TGC M~A GCT GIT  AAC ACC CTT  GGG GAA GCC AC6 TGT  ACC C-CA  ~A  CTC 6TT  4367 
1199  Gly ksn Cys  5or  Leu  Thr  Tie  5er 01u  Ve]  Cy$ 61y  Asp Asp Asp Ala lys  Tyr  The  Cys  Lys  Ala  Val  Asn  5or  Leu &ly  Glu  Ma  lhr  Cys  Thr  A~a Glu leu  Leu 
GTG ~  ACA ATG GraA AAA ~  G£aA ~  ~  ~  ~  ~  G~¢A G~  C¢~A  ~T  ~  G),G  ~  GAG ~  G/LA  IGAaacaaggetcaaagaaaacaaaaaaaaaaeaaa  4472 
1235  Val  61u  Thr Net Gly Lys  Glu Gly Glu Gly 6]u  Gly 61u  Gly 61u  Glu Asp Glu 61u Glu filu Glu 6]u  01~  1257 
Figure 2.  The DNA sequence of the fi- 
broblast MLCK encodes a unique pro- 
tein. The nucleotide sequence established 
by the strategy  outlined in Fig.  1 B  is 
shown along with the translated amino 
acid sequence for fibroblast MLCK. 
These sequence data are available from 
EMBL/GenBank/DDJB  under accession 
number X52876.  Numbering of the DNA 
sequence is shown in the right margin; 
amino acid sequence numbering is shown 
in the left margin.  The portion  of the 
DNA sequence that represents the open 
reading frame is given in upper case let- 
ters. Amino acid residue numbering was 
started at Asp-l, the first amino acid fol- 
lowing the initiator ATG. As described 
in the text,  selected sequences were de- 
termined by automated  amino acid se- 
quence analysis as part of the clone veri- 
fication experiments.  These regions are 
underlined. 
The Journal  of Cell Biology, Volume 111, 1990  1110 Step 1 was cell disruption. Frozen bacterial cell pellets were thawed on 
ice (if necessary), resuspended in 5 vol of buffer B (50 mM Tris-HCl pH 
7.5, 1 mM DTT, 1 mM EGTA, 5 mM EDTA), sonicated four times for 20 s 
on ice using the microtip on a sonicator (Branson Sonic Power Co., Dan- 
bury, CT). The mixture was centrifuged at 4°C (20 rain, 3,000 g). 
Step 2 was ammonium sulfate fractionation. The cleared lysate was ad- 
justed to a final volume of 300 ml, brought to a final concentration of 1.4 M 
(Nl-hhSO4, stirred 20 rain at 4°C, and centrifuged at 4'~C (20 rain, 20000 g). 
The supernatant was recovered,  adjusted to a final concentration of 2.1 M 
(NH4)2SO4, stirred 20 min at 4°C, and centrifuged again (4°C,  20 rain, 
20,000 g). The final pellet, which contained the majority of the MLCK ac- 
tivity, was resuspended in buffer B. 
Step 3 was phenyl-Sepharose chromatography.  Clarified  solutions con- 
taining enzymes were adjusted  to a volume of 300 ml, brought to a final 
concentration of 1.4 M (NH4)2SO4, stirred 20 min at 4°C, and centrifuged 
(4°C, 20 min, 20,000 g). The supernatant was loaded at a flow rate 0f2.5 
ml/min onto a phenyI-Sepharose  column (10 ml bed volume) previously 
equilibrated with buffer  C  (buffer  B containing 1.4 M  (NH4)2SO4), and 
washed with 150 ml of buffer (2. Proteins were eluted with a linear gradient 
from  1.4 to 0  M  (NH4)2SO4 using a 650 Advanced  Protein Purification 
Systems  (Waters Associates,  Inc., Rochester,  MN).  Fractions containing 
MLCK activity  were pooled. 
Step 4  was  DEAE-Sepharose chromatography.  The pooled fractions 
were diluted with buffer D (50 mM Tris-HC1 pH 7.5, 1 mM I)TT,  1 mM 
EGTA) to a conductivity of ~8 mmho. The solution was loaded at a flow 
rate of  4 ml/min onto DEAE-Sepharose Fast Flow (Pharmacia Inc.) column 
(20 mi bed volume) previously equilibrated in buffer D. The column was 
washed with 15 vol of buffer D, and proteins eluted using a linear gradient 
from 0 to 700 mM NaCI. Fractions containing MLCK activity were pooled. 
Step 5 was CaM-Sepharose chromatography.  Fractions containing en- 
zyme were diluted to 300 ml with buffer E (50 mM Tris-HCl pH 7.5, 1 mM 
DTT, 3 mM MgCI2, 3 mM CaCI2, 50 mM NaC1), adjusted to a final con- 
centration of 2 mM CaCI2, and loaded at a flow rate of 1 ml/min onto a 
CaM-Sepharose column (20 ml bed volume) prepared as described (52). 
The column was washed with 5 vol of buffer E, followed by 2.5 vol of buffer 
F (50 mM Tris-HCl pH 7.5, 1 mM DTT, 3 mM MgCI2, 1 mM CaCI2, 600 
mM NaC1), and the proteins were eluted with 75 ml of buffer G (50 mM 
Tris-HCl, pH 7.5,  1 mM  D'I'T, 3  mM MgCI2,  200  mM NaCI,  2  mM 
EGTA). Fractions containing MLCK activity were pooled. 
Step 6 was Mono-S HR5/5 (Pharmacia Inc.) cation exchange chromatog- 
raphy. Fractions containing MLCK activity were diluted to a final volume 
of 50 mi using buffer H (50 mM Hepes pH 7.0, 1 mM DTT, 1 mM EGTA), 
and loaded at a flow rate of 0.5 ml/min onto a Mono-S-Sepharose column. 
The protein was eluted using a linear gradient from 0 to 700 mM NaCI. 
Fractions containing MLCK activity were aliquoted and stored at -20°C. 
The purification of CaM binding protein kinases consisted of steps 1, 3, 
5, and 6. The purification of the non-CaM binding protein kinases consisted 
of steps  1-4 and 6. For activity screening,  purification  of mutant rMLCKs 
consisted only of steps  1 and 5 with appropriately adjusted  volumes. 
Protein Kinase Activity Assays and Gel Methods 
The phosphotransferase activity of rMLCK1, chicken gizzard MLCK, and 
mutant protein kinases from [3,-~2p]ATP  to a peptide substrate or chicken 
gizzard myosin light chains were determined as previously described (80). 
Briefly, standard assay conditions at 25°C, were 0.2 mM [3,-3-'P]ATE 50 
t~M peptide substrate (KKRI~RATSNVFAM),  0A  mM CaCI2,  5  mM 
MgC12, 1 mM ITIT, 0.1 mg/ml BSA, 50 mM Hepes pH 7.5, CaM as indi- 
cated, and kinase. The CaMPK-II peptide substrate (PLRRTLSVAA) and 
the cAMP-dependent protein kinase peptide substrate (LRRASLG) were 
used at 50/~M where applicable.  The CaMPK-II peptide substrate was a 
gift from Dr.  Marita King (Ohio State University,  Columbus, OH). The 
cAMP-dependent  protein kinase peptide  substrate was  purchased from 
Sigma Chemical Co.  (St.  Louis, MO). 
The apparent Kms of the peptide substrate with rMLCK1,  mutant pro- 
tein kinases, and gizzard MLCK were determined at saturating levels of 
CaMs (wild type, E84K mutant, or E120K mutant) and 2 nM enzyme under 
the standard assay conditions.  The concentration of the peptide  substrate 
was varied from 6.3 to 500 #M. The apparent Kr~s were calculated  with the 
assistance of Graph Pad (version 2 program; copyright  1985-1987 by H. J. 
Motulsky; distributed by Institute for Scientific Information Software, Phil- 
adelphia, PA) using intercepts of linear regression lines from double recip- 
rocal plots according to the data treatment of Lineweaver and Burk (47). 
SDS-PAGE and CaM overlays were done as described by Burgess et al. 
(9).  Western blot analyses were done as previously  described by Burgess 
and co-workers  (9, 75) using a polyclonal  rabbit antibody against chicken 
gizzard  MLCK. 
Computer-based Sequence Analysis 
Amino acid sequence comparisons were done using the program FASTA 
(62). Nucleic acid or protein sequence database searches used the FAS~DB 
program  from  the  Intetligenetics program  suite  (Version  5.35;  Intel- 
ligenetics,  Mountainview,  CA). The databases searched were Genbank re- 
lease 61.0 (9/89)  and PIR (Protein Identification  Resource)  release 21.0 
(6/89).  Amino acid sequence motif analysis was done with the pattern 
searching program QUEST (Intelligenetics).  The previously described mo- 
tifs of Benian et al.  (6) were optimized for finding  related sequences in 
fibroblast MLCK. Analysis of fibroblast MLCK for additional repeated mo- 
tifs was initiated by manual inspection and then optimized with the QUEST 
program. All of the above programs were run on a SUN Microsystems com- 
puter workstation.  Analysis of the fibroblast  MLCK amino acid sequence 
for potential phosphorylation and glycosylation  sites was done using the 
program PROSITE  within the PCGENE (version 6.01) program package 
(Intelligenetics).  Helical wheel projections and the calculation of hydropho- 
bic moments were done with the PCGENE program HELWHEEL accord- 
ing to the method of Eisenberg et al. (18). 
Results 
Chicken Fibroblast MLCK Has a Unique, Segmentally 
Organized Amino Acid Sequence 
A set of cloned plasmid DNAs were isolated from a eDNA 
library (secondary culture CEF), mapped by restriction en- 
donuclease  digestion,  and characterized by DNA sequence 
analysis (see Materials and Methods and Fig.  1).  DNA se- 
quence analysis demonstrated that the three clones indicated 
in  Fig.  1 A  contained  overlapping DNA  sequences.  The 
strategy that resulted in the elucidation of the entire DNA se- 
quence is shown in Fig.  1 B, and summarizes the minimal 
data required to establish the complete DNA sequence. Ad- 
ditional sequence  data were generated for confirmation of 
the proposed final DNA sequence. 
The nucleotide sequence obtained is summarized in Fig. 
2. The DNA sequence has an open reading frame of 3,774 
bases that begins with an ATG translation initiation c,~don at 
nucleotide 663. This DNA sequence encodes an amino acid 
sequence of 1,257 residues with a computed mass of 139,594. 
The computed mass is in general agreement with the esti- 
mated molecular weight,  based on SDS-PAGE analysis, of 
avian gizzard (smooth muscle)  (1,  17, 56,  79) MLCK and 
mammalian nmMLCK (8). However, the computed mass of 
chicken gizzard MLCK is only 107,534 (58), raising the pos- 
sibility  that the  estimated  molecular  weight  of fibroblast 
MLCK, based on SDS-PAGE, may be closer in magnitude 
to its  computed  mass  than that for gizzard  MLCK.  The 
length of the fibroblast cDNA is also consistent with the esti- 
mated size of the mRNA for fibroblast MLCK (76). Overall, 
confirmation of the identity of the cloned DNA as encoding 
an  MLCK  is indicated  by  the: (a)  ability  to produce  an 
MLCK activity  from the cloned  DNA (shown in succeed- 
ing sections of this report); (b) general agreement between 
the computed mass and the estimated molecular weight of 
nmMLCK; (c) exact agreement between the translated amino 
acid sequence and elucidated amino acid sequences  for se- 
lected peptides from a tissue-isolated  enzyme;  and (d) im- 
munoreactivity with anti-MLCK  antibodies of the protein 
product produced by expression cloning. 
A search of databases reve~ed that the closest match to 
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was the partial sequences of chicken gizzard MLCK. In ad- 
dition, the remainder of the DNA sequence of a cDNA en- 
coding chicken gizzard MLCK was reported (58) while this 
manuscript was under review. Altogether, the differences be- 
tween the chicken fibroblast MLCK cDNA sequence and 
that for chicken gizzard MLCK fall into four categories: (a) 
the complete DNA sequence of fibroblast MLCK reported 
here is at least 1,220 bp longer at the 5' end than that reported 
(58) for gizzard MLCK, resulting in a significantly shorter 
open reading frame for gizzard MLCK compared to fibro- 
blast MLCK; (b) different DNA sequences between nucleo- 
tides  1,220  and  1,229  of fibroblast MLCK cDNA  (corre- 
sponding to nucleotides 1-9 of the gizzard MLCK cDNA); 
(c) a single base pair difference at nucleotide 3,034 (G-3034 
in fibroblast, A-1815 in gizzard) that results in a potential 
coding difference; and (d) a  set of single base pair differ- 
ences corresponding to the position of nucleotides 3,527, 
3,653, 3,701 and 3,755 of the fibroblast cDNA sequence. 
The potential importance of the differences between the 
cDNAs encoding fibroblast or gizzard MLCK can be par- 
tially addressed based on the results of our studies, and an 
analysis of the reports by Guerriero et al. (23) and Olson et 
al. (58).  The DNA sequence of the cDNA encoding gizzard 
MLCK (23, 58) appears to be significantly shorter in its open 
reading frame, and there is a major divergence in the DNA 
sequence identity between the gizzard and fibroblast cDNAs 
in the first 9 bp of  the noncoding region of  the gizzard MLCK 
cDNA. A DNA sequence corresponding to nucleotides 1-9 
of the gizzard cDNA is not found in the fibroblast cDNA. 
The DNA sequence in this region of  the fibroblast cDNA was 
established by overlapping sequence analysis of both strands, 
twice on each strand, diminishing the probability of a techni- 
cal artifact in the sequence analysis. Although current stud- 
ies of the genomic DNA sequence should provide insight 
into the biosynthetic basis of this major difference between 
fibroblast and gizzard MLCKs, it is reasonable to speculate 
that the two cDNAs might be derived from the same gene 
by either alternative splicing or promotion. This type of bio- 
synthetic relationship could produce in smooth muscle tissue 
an MLCK that is shorter in length than nmMLCK, has ex- 
tensive DNA sequence identity with nmMLCK, and has a 
major divergence from the nmMLCK cDNA in the 5' non- 
coding region of the cDNA. 
The single base pair difference between the fibroblast and 
gizzard cDNA sequences at the position corresponding to 
G-3034  of the fibroblast cDNA would result in a  coding 
difference between the two MLCKs (arginine in fibroblast 
MLCK and glutamine in gizzard MLCK). No protein se- 
quence analysis data for either MLCK is available  for this 
region. However, the sequence of  the fibroblast cDNA deter- 
mined as part of this report was characterized from five 
different sequence reactions on three different cloned DNA 
inserts purified from two different flbroblast cDNA libraries. 
The DNA sequence of the gizzard cDNA (23, 58) was eluci- 
dated from two different clones isolated from two different 
gizzard libraries.  Thus, this difference in DNA  sequence, 
like that for the 5' ends of both cDNAs, needs to be inves- 
tigated further. 
The differences in DNA sequence between the fibroblast 
and gizzard cDNAs at positions corresponding to nucleo- 
tides 3,527, 3,653, 3,701, and 3,755 of the fibroblast cDNA 
appear to correlate with a  given sample of cloned DNA, 
based on the limited data available.  Briefly, we determined 
the DNA sequence of this region from multiple DNA sam- 
pies purified from two different fibroblast cDNA libraries 
and one gizzard cDNA library. Interestingly, in all cases the 
DNA sequence at these positions was either C or T, and all 
of the differences found would be silent in terms of coding 
potential. Further investigation of this observation was not 
done as part of this study, and the DNA sequence given in 
Fig. 2 is that obtained for the clones shown in Fig. 1 A. At 
this time, the presence of a C or T at these positions for either 
the fibroblast or gizzard cDNAs must be considered equivo- 
cal and possibly dependent on the molecular cloning history 
of the insert. 
In contrast to the extensive stretches of DNA and amino 
acid sequence identity between smMLCK and nmMLCK, 
there is only a 29 % identity between the cDNAs encoding 
nmMLCK and skMLCK. Overall, the database and litera- 
ture searches revealed that the nmMLCK is the longest poly- 
peptide chain for a CaM-regulated protein kinase that has 
been characterized, including the closely related smMLCK, 
and is twice the length of the skMLCK. 
The amino acid sequence of nmMLCK can be divided ar- 
bitrarily into segments based on sequence similarity to other 
protein kinases and to other CaM regulated protein kinases 
(Fig. 3). For example, all of the conserved residues noted by 
Hanks et al. (24) in their analysis of protein kinases are con- 
tained in the nmMLCK sequence.  In addition, there are 
other  segments that have  extensive amino  acid  sequence 
similarity with other CaM-regulated protein kinases (Fig. 
3).  Studies implicating specific segments in catalytic and 
regulatory function have been done (this report). The func- 
tional significance of amino acids 1,048-1,067,  another re- 
gion of sequence similarity noted in Fig. 3, is not known. 
However,  the  occurrence between potential catalytic and 
regulatory segments, and apparent conservation among cer- 
tain regulated protein kinases, raised the possibility of func- 
tional importance.  The COOH-terminal segment (Fig.  2) 
might be identical in amino acid sequence to a protein called 
KRP or telokin, that can be isolated from homogenates of 
chicken gizzard tissue (Shattuck, R. L., and D. M. Watter- 
son, unpublished data; 40), although it has not been shown 
yet that KRP/telokin is a unique transcript rather than a pro- 
teolytic fragment of smMLCK. 
Sequence Motifs Outside of the Catalytic and CaM 
Regulatory Segments 
The amino acid sequences of nmMLCK and smMLCK di- 
verge significantly from skMLCK and other CaM regulated 
protein kinases in the amino terminal tail and the COOH ter- 
minal segments. These segments of nmMLCK have two se- 
quence motifs that are found in receptors, and the tail seg- 
ment has a third repeated motif that appears to be specific 
to nmMLCK and smMLCK (Fig. 4). Benian et al. (6) noted 
the presence of sequence motifs I and II in neural adhesion 
molecules (NCAMs), twitchin (a protein encoded by a Cae- 
norhabditis elegans gene that is altered in motility mutants), 
the receptor for PDGE and the partial amino acid sequence 
of gizzard MLCK. Based on the characteristics of the pro- 
teins in which these motifs are found, Benian et al. (6) raised 
the possibility that these motifs might be involved in subcel- 
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skMLCK 
519 
ACKVLVEDT~$TKAAK~AEKK~KKPKTTLPPVLSTE~EATVKKKPA~KT~PY~TP~QIT~FPE0RKVRAGESVELFAKVVGTAPITCT~KFRKQIQENEYIKIENAEN~KLTI~TKQEH~GCYTLVV  650 
:  :  :  ::  :  :  :  :  :  :  ::  :  :  :  : 
~IQSL~TDEA~K6AASEE~LAAEK~PAP~EKGP~P~TK~DP~P~TPKK~ANTPAPEK6DVVPAQPSA~GSQ6PAGEG6QVEAPAEG~AGK~AAL~QQTATAEASEKKPEAEK~P~GHQ~PGEPTVGKKV  141 
10 
nmMLCK 
skMLCK 
ENKLBSRQAQVNLTVVDKPDPPAGTPCASD  I RSS  S  LTLSWYBSSYD66SAVQSYTVE  IWNSVDNKWTOLTTCRST$ FNVQDLQAOR  EYKFRVRAANVY61SEPSQESEVVKVGEKQEEELKEEEAELSDDEG  782 
:  :  :  :  : 
AEGQAAARRGS  PAFLHSPSCPA  I IASTEKLPAQKPLSEASE[  I FEGVPATPGPTEPGPAKAEBGVOLLAESQKEAGEKAPGQADQAKVOGDTSRGI  EFQAVPSERPRPEVBQALCLPAREEDCFQI  LDDCPP  273 
nmMLCK 
skMLCK 
CaMPK-II 
KETEVNYRTVTINTE~KVSD-VYNIEERLGSGKFGQVFRLVEKKTGKVWA~KFF--KAYsAKEKENIRDEIsIMNCLH~PKLVQCV~AFEEKANIVMVLEMVs~GELFERIIDE~FEL-TERECIKYMRQI~  910 
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CaMPK-II 
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Figure 3. Extended amino acid sequence identities between nmMLCK and skMLCK are limited to catalytic and CaM regulatory regions. 
Comparison of the two MLCKs (this report and reference 73) and beta subunit of CaMPK-II (7) demonstrates that the extent of amino 
acid sequence identity between nmMLCK and skMLCK is characteristic of CaM-regulated protein kinases. The colon indicates positions 
of amino acid sequence identity with nmMLCK. The numerals indicate amino acid residues for each kinase. The asterisk marks the first 
and last conserved amino acids in the catalytic region of protein kinases as defined by Hanks et al. (24). The diagonal symbols denote 
the approximate boundaries of the calmodulin regulatory region, which includes the AM13/RS20 regions (see Fig. 5). The pound symbols 
denote a conserved region found in CaM-regulated and other regulated protein kinases, nmMLCK and smMLCK have sequence motifs 
in the tail segment that are similar to those found in receptor proteins, and have a unique motif (Motif III) that is repeated (see Fig. 4). 
The overlining indicates the position of motifs in this region. The portion of nmMLCK shown here is included in rMLCK1 (Fig. 5). 
lular targeting or folding of the proteins.  The location of 
these sequence motifs, called motif I and II, in the fibroblast 
MLCK sequence are shown in Fig. 4 along with a compari- 
son to a similar sequence from NCAM or PDGF receptor. 
For ease of comparison these have been divided into motifs 
Ia, Ib, Ha, and lib. 
Amino acid sequence motif III, which we detected during 
the analysis of the fibroblast MLCK sequence (Fig. 4), oc- 
curs  four times in the tail  segment.  At this time,  this re- 
peated motif pattern appears to be unique to nmMLCK and 
smMLCK. Database searches based upon motif III did not 
yield other proteins with this  specific arrangement.  How- 
ever, similarity searches with a region of fibroblast MLCK 
(residues 300-500) that contains motif HI sequences, found 
proteins with proline-rich regions (e.g., histone H1, neuro- 
filament triplet H protein, and the Abl transforming tyrosine 
kinase). Currently, the functional significance of  motifs I, II, 
and III in MLCK or other proteins is not known. However, 
based upon their relative positions within MLCK and the 
types of other proteins in which they are found, the sugges- 
tion (6) that they may be involved in subcellular targeting is 
reasonable. Relatedly, these motifs might be key in the fold- 
ing of a common type of protein structural domain. 
MLCK  has  potential  N-glycosylation sequences  (e.g., 
residues 358, 629, 662, and  1,200), but there has been no 
evidence to date  to  indicate  that  MLCK is  glycosylated. 
Computer algorithms (see Material and Methods) also reveal 
a  number of potential phosphorylation sites (Table I). Al- 
together, there is the potential of fibroblast MLCK being a 
substrate for at least six different protein kinases. 
rMLCK1 Is Indistinguishable from ~ssue-isolated 
MLCK in its Kinetic and Regulatory Properties 
The catalytic and  CaM  regulatory segments  of fibroblast 
MLCK, tentatively identified by sequence comparison (Fig. 
3),  were correlated with  CaM-regulated catalytic activity 
(Fig. 6 and Table II) by the production oft protein, rMLCK1 
(sequence data are available from EMBL/GenBank/DDJB 
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Figure 4. Sequence motifs found in membrane and functionally unrelated proteins are present in the tail and KRP-like segments of fibroblast 
MLCK. Previously identified (6) amino acid sequence motifs (I and ]]) are present in tibroblast MLCK. In addition, a new motif (motif 
lid has been identified. Motifs ! and 1I from fibroblast MLCK are compared to examples  from neuron cell adhesion molecule (NCAM; 
71), and the PDGF receptor (22). Amino acid sequences  of NCAM and PDGF receptor are from the PIR protein sequence  database  entries 
S00846 and A28206, respectively.  Boxes  indicate positions where the same  amino acid is present in at least 50% of the sequences.  Numerals 
indicate amino acid residue number in the sequence. 
under accession number X52877), that includes amino acid 
residues 519-1,116 (Figs. 3 and 5). rMLCK1 is the same net 
length as skMLCK and includes a set of nmMLCK motifs 
from the tail segment, rMLCK1 was made by expression 
cloning in E.  coli, and was purified through a CaM-Seph- 
arose chromatography step. Like the MLCK activity purified 
from chicken gizzard, rMLCK1 has no detectable activity 
under standard assay conditions in the absence of CaM, and 
requires the presence of the calcium/CaM complex for activ- 
ity. rMLCK1 is also similar to chicken gizzard MLCK in the 
concentration of CaM required for half-maximal stimula- 
tion. Thus, rMLCK1 includes the catalytic, autoinhibitory, 
and CaM recognition functions of fibroblast MLCK. 
rMLCK1 responds to mutations in CaM similar to tissue- 
isolated MLCK (Fig. 6 and Table II). Point mutations at E84 
and El20 of CaM result in an increase in the apparent Km of 
the CaM/MLCK and CaM/rMLCK1 complex for peptide 
substrate (Table II). Although apparent effects on Vr,  ax were 
also noted, the consistent trend with the CaM mutations is 
to increase the apparent Km of the complex.  The peptide 
substrate specificity of rMLCK1 also resembles that of giz- 
zard MLCK. When peptide substrates for other protein ki- 
nases such as CaMPK-II or cAMP-dependent protein kinase 
were tested at concentrations similar to that of  the light chain 
peptide substrate (50 #M), rMLCK1 had <10% of the phos- 
photransferase activity it had with the myosin light chain 
peptide substrate (data not shown). Therefore, rMLCK1 has 
the kinetic properties, peptide substrate sp.e.  cificity, and CaM 
recognition properties of an MLCK isolated from a verte- 
brate tissue. 
Design, Production,  and Analysis of a 
Suppressor Mutant 
Results from studies that used peptide analogues of residues 
1,082=1,101  in the MLCK sequence (48,  50),  site-specific 
mutagenesis, and computational chemistry analyses of CaM 
(14, 80; Table 1I), and enzyme kinetic studies of CaM/MLCK 
complexes (Table II) raised the possibility of complementary 
charge features within CaM and MLCK that are important 
in  the  formation and  functioning of CaM/MLCK signal 
transduction complexes. The potential importance of protein 
charge, or electrostatic, properties in biological macromole- 
cular recognition has been recognized for some time (59), 
and the specific data that showed (14, 80) that charge reversal 
mutations of CaM alter its ability to interact with MLCK are 
consistent with this possibility. If there is a complementary 
charge component to CaM/MLCK recognition and function, 
then it might be possible to engineer a suppressor mutant of 
MLCK by using charge reversal mutagenesis of MLCK be- 
tween residues 1,082-1,101. A suppressor mutation is one in 
which a mutation of one member (e.g., MLCK) of a pair of 
interacting proteins (e.g., CaM and MLCK) can compensate 
for, or suppress, the effects of a mutation in the other compo- 
nent (e.g., CAM). 
As a direct test of this chemical complementarity hypothe- 
sis we changed the positively charged Arg-Arg-Lys sequence 
in MLCK (residues  1,082-1,084)  to a  Glu-Glu-Glu nega- 
tively charged cluster, and tested the ability of this mutant 
MLCK to  suppress  the  functional effects  of Glu  to  Lys 
changes in CaM. The resultant enzyme, rMLCK2 (Fig. 5), 
The Journal of Cell Biology, Volume  111, 1990  1114 Table L Potential Sites in Nonmuscle 
and Smooth Muscle Myosin Light Chain Kinases  for 
Phosphorylation by Other Protein Kinases* 
cAMP/cGMP  Protein  Casein  Tyrosine  cdc2 
kinases  CaMPK-II  kinase C*  kinase II  kinase  kinase 
Ser-219  Thr-96  Thr-55  Thr-76  Thr-46  Thr-568 
Ser-269  Ser-179  Ser-249  Thr-130  Thr-621 
Thr-325  Thr-242  Ser-269  Ser-181 
Ser-1072  Thr-246  Thr-325  Ser-194 
Ser-1100§  Ser-372  Thr-438  Ser-218 
Ser-1113§  Ser-460  Ser-477  Ser-272 
Ser-685  Ser-529  Ser-274 
Ser-726  Thr-540  Thr-300 
Thr-793  Thr-559  Ser-302 
Ser-812  Ser-630  Ser-436 
Ser-910  Ser-637  Thr-638 
Ser-954  Thr-721  Thr-664 
Ser-1100§  Ser-812  Ser-693 
Ser-I 113  Ser-826  Ser-778 
Ser-839  Ser-839 
Thr-898  Ser-882 
Ser-940  Thr-898 
Ser-957  Thr-  1150 
Ser-1108  Thr-1204 
Thr-1217  Ser-1223 
* Detected using the PROSITE program (See Materials and Methods) except 
as noted.  Residue numbers are those of nmMLCK (this report),  CaMPK-II 
(CaM-dependent protein kinase II) sites are based on the consensus sequence 
Arg-X-Y-Ser/Thr (69), while the cdc2 kinase site was located with the consen- 
sus, Ser/Thr-Pro-X-Lys (63). 
¢ Protein kinase C  phosphorylates smMLCK (57),  but sites have not been 
identified. 
§ Indicates that a particular site has been verified experimentally (28, 48, 60, 
61) in a smooth or nonmuscte MLCK. Ser-1100 in MLCK was not detected 
by PROSITE. 
was able to suppress the kinetic effects of charge reversal mu- 
tations  in  CaM  in  which  glutamic  acid  residues  were 
changed to lysines (Table II). rMLCK2 remained CaM de- 
pendent, indicating that the suppression is not due to a loss 
of intramolecular inhibition. As summarized in Table II, the 
trend of an increased apparent K~ for peptide substrate by 
enzyme complexes that contain mutant CaMs and wild-type 
protein kinases is reversed toward normal when the complex 
contained rMLCK2. An equivalent suppressor effect was not 
seen with other charge reversal mutations in this sequence 
(e.g., rMLCK3, rMLCK4, or rMLCK5), indicating that the 
full suppressor effect requires the cluster charge reversal. 
A Chimeric nmMLCK/skMLCK Enzyme Is 
lsofunctional with nmMLCK 
The ability of  mutations in the RS20 region of MLCK to sup- 
press the functional effects of CaM mutations (rMLCK2; 
Fig. 5), combined with the previous demonstration (48, 50) 
that fragments and peptide analogues of this sequence have 
selective high affinity CaM binding activity, provides a more 
formalized proof that this region of MLCK is quantitatively 
important in CaM recognition. To explore further the molec- 
ular basis of the selective recognition of CaM by MLCK and 
test for functional differences in CaM recognition and regu- 
lation between the nmMLCK and skMLCKs, we produced 
and  characterized a  chimeric  enzyme in  which  residues 
1,081-1,099  of the  rMLCK1  were replaced by the  corre- 
sponding sequence from skMLCK (Fig.  5).  The enzyme, 
Table II. Analysis of  a MLCK Suppressor Mutant 
Produced by Site-specific Mutagenesis of  the CaM 
Recognition Sequence* 
CaM/MLCK complex 
Protein kinase  Calmodulin*  Peptide substrate K~§  Ratioll 
/zM 
W.T.  10.6  +  2.5  (11)  1,0 
MLCK  +  E84K mutant  40.8  +  6.0  (3)  3.8 
(wild type)  E120K mutant  65.2  +  10.5  (3)  6.2 
W.T.  11.1  +  2.8  (13)  1.0 
rMLCK1  +  E84K mutant  47.5  +  6.6  (8)  4.3 
(wild  type)  E120K mutant  85.6  +  17.4  (9)  7.7 
W.T.  10.9 + 3.7  (10)  1.0 
rMLCK2  +  E84K  mutant  16.0 5- 5.3  (7)  1.5 
(suppressor  EI20K mutant  18.3 5- 4.0  (6)  1.7 
mutant) 
* rMLCK2 differs from rMLCKI only at the three charge reversal mutation 
sites (see Fig. 5), yet it is able to suppress the functional effects of CaM muta- 
tions (compare ratios of complexes containing wild-type or mutant CaMs). 
MLCK, rMLCKI, and rMLCK2 have no detectable activity in the absence of 
calcium and CaM under the assay conditions used. 
* Wild-type  (W.T.)  calmodulin  refers  to  either  tissue-isolated  vertebrate 
calmodulin, recombinant DNA encoded and produced vertebrate calmodulin, 
or VU-1 (SYNCAM) calmodulin. These are functionally equivalent under the 
conditions used. The mutant calmodnlins differ from SYNCAM calmodulin 
only at the single sites noted (E84 and El20).  At least a fourfold excess of 
calmodulin (0.2-3 #M) over the concentration required to achieve maximal ac- 
tivation was used in these determinations. 
§ The values represent the average apparent K= 5: the standard deviation for 
the number, in parentheses, of experiments (see Materials and Methods). 
Km of protein kinase activated by a given calmodulin 
tt Ratio = 
Km of same protein kinase activated by wild-type calmodulin 
The ratio of the Kr~'S of a protein kinase activated by wild-type calmodulin is 
1.0. An increase in the ratio indicates the decreased ability of a given calmodu- 
lin to activate  that protein kinase. 
termed rMLCK6, was produced in E. coli, purified through 
CaM-Sepharose chromatography, and characterized in terms 
of its responses to wild-type and mutant CaMs (Fig. 6). 
rMLCK6 is functionally indistinguishable from rMLCK1. 
rMLCK6 requires CaM for activity, thereby demonstrating 
that the autoinhibition activity has not been disturbed. The 
concentration of CaM required for half-maximal stimulation 
of rMLCK6 is similar to that of rMLCK1, as is the response 
to the E84K and E120K mutant CaMs (Fig. 6). These data, 
combined with the results of the following sections, demon- 
strate that more than one amino acid sequence can produce 
the same CaM recognition properties within the context of 
an active, CaM-dependent enzyme, and suggest a consensus 
CaM  recognition  sequence  for  MLCKs.  As  a  caveat,  it 
should be noted that the results do not mean that the second- 
ary and tertiary structures are equivalent; the results do raise 
the possibility that more than one structure can accomplish 
the same function. 
CaMPK-II CaM Binding Sequences in 
MLCK Convert the CaM Recognition Properties 
of MLCK toward Those of CaMPK-H 
Previous studies have shown (80) that CaMPK-II is less sen- 
sitive than MLCK to the E84K mutation in CaM. CaMPK-II 
also has a region of amino acid sequence with a high degree 
of similarity to the RS20 region of MLCK (Fig.  3),  Like 
MLCK, peptide analogue studies of CaMPK-II sequences 
Shoemaker et al. Nonmuscle Myosin Light Chain Kinase  1115 Figure 5.  Summary of the primary structure  and functional properties  of the 20 mutant MLCKs used in this study. The ability (+) or 
inability (-) of each protein ldnase either to bind CaM, phosphorylate peptide substrate, or be activated by CaM is indicated. The portion 
of the fibroblast MLCK sequence shown in Fig. 3 encodes a CaM-dependent MLCK activity (rMLCKI). This sequence contains the cata- 
lytic and proposed CaM regulatory segments as well as a set of tail segment motifs identified in Fig. 4.  Shown here is a comparison of 
the amino acid sequences within the CaM regulatory segment (AM13/autoinhibitory region and RS20/CaM recognition region) of the 20 
MLCK mutants to that of the parent rMLCK1; only the differences in amino acid sequence between the mutants and rMLCK1 are shown, 
For rMLCK14,  15, and  16 the diagonal symbol indicates the carboxy terminus of these proteins. 
have implicated this region of CaMPK-II in CaM binding 
(25). Therefore, as an attempt to gain additional insight into 
the molecular basis of differential CaM recognition by pro- 
tein kinases (80), we made and characterized a chimeric en- 
zyme in which a portion of the RS20 region of MLCK was 
replaced by the corresponding sequence from CaMPK-II. 
The chimeric enzyme, termed rMLCK7 (Fig. 5), responded 
(Fig. 6) to wild-type and mutant CaMs similar to CaMPK- 
II, but the autoinhibition,  substrate recognition, and phos- 
photransferase  activities  of MLCK  were  maintained.  As 
with CaMPK-II isolated from vertebrate tissue (80), the con- 
centration of CaM required for half-maximal activation of 
rMLCK7 is greater than that seen with MLCK or rMLCK1. 
Similarly, the comparative lack of sensitivity of rMLCK7 to 
the E84K CaM mutation is reminiscent of  that seen (80) with 
tissue-isolated CaMPK-II. Thus, there is a partial suppressor 
effect of substituting the CaMPK-II sequence for the MLCK 
sequence in the RS20 region.  A  series of point and cluster 
mutations  in  which  the  MLCK  consensus  sequence  was 
converted to the CaMPK-II sequence in this region resulted 
in  an  increase  in  the  concentration  of CaM  required  for 
half-maximal activity like that seen with CaMPK-II and the 
MLCK/CaMPK-II chimeric enzyme (rMLCK7).  However, 
the  partial  suppressor  effect  seen  with  CaMPK-II  and 
rMLCK7 was not seen with partial replacements, such as the 
changes found in rMLCK8, rMLCK9, rMLCK10, rMLCK11, 
and rMLCK12 (Fig. 5).  This indicates that the differential 
response of rMLCK7 to mutant CaMs may be a  feature of 
some combination of the several sequence differences from 
the consensus MLCK sequence. This possibility was not in- 
vestigated further as part of this study. 
Overall, the ability to generate, by altering the RS20 re- 
gion  of  MLCK,  enzymes  that  maintain  their  substrate 
specificity but respond differentially to wild-type and mutant 
CaMs supports the hypothesis (48) that the RS20 region of 
nmMLCK and smMLCK is quantitatively important in CaM 
recognition. The MLCK mutants described in this and the 
preceding  sections  are  like  smMLCK  in  their  lack  of 
The Journal of Cell Biology, Volume 111,  1990  1116 Figure 6. The CaM recognition features of fibroblast MLCK can 
be converted to those of CaMPK II by changing the RS20 region. 
The CaM binding region, RS20, of rMLCK1 was replaced with the 
corresponding sequences from skMLCK (rMLCK6) or CaMPK-II 
(rMLCK7). The resultant amino acid sequences are shown in Fig. 
5. Shown here is the dose-dependent activation of each protein ki- 
nase by wild type (W.T.) or mutant CaMs. The mutant CaMs con- 
tain single Glu to Lys substitutions (E84K or E120K). The ordinate 
refers to the activity of each kinase on a 0-I.0 scale, where 1.0 is 
the maximum activity obtained with wild-type CaM, for each pro- 
tein kinase. Error bars indicate the range of duplicate determina- 
tions. Each CaM concentration is represented by a bar: 3 (vertically 
striped),  6  (speckled), 10  (crosshatched), 30  (diagonal), 60 
(horizontal), 260 (solid), 1,200 nM (open), and 8,000 nM (win- 
dowpane). 
significant activity with caltractin (data not shown), a natu- 
rally occurring CaM analogue (36). This demonstrates that 
the gross recognition features that allow discrimination be- 
tween CaM and closely related analogues found in the same 
cell are maintained in these mutant MLCK, even when there 
are changes in response to wild-type and mutant CaMs. 
Inversion of the Sequence within the CaM 
Binding Region Results in a Protein That Is Still CaM 
Dependent and Not Constitutively Active 
All of the mutant MLCKs described in the preceding sec- 
tions are CaM dependent, i.e., they are not constitutively ac- 
tive.  This is  noteworthy because altogether the mutations 
(see Fig. 5) involved changing most of the amino acids that 
have been implicated in some autoinhibition models, and all 
of the critical amino acids of the pseudosubstrate hypothesis 
(61) have been altered. This raises concerns about some of 
the basic assumptions of the autoinhibition models in which 
the autoinhibitory sequences of MLCKs have been equated 
with the CaM binding sequences. Therefore, we produced a 
mutant MLCK (rMLCK13) in which the sequence within 
this region was inverted (Fig. 5) as part of an attempt to fur- 
ther explore the basic assumptions of autoinhibition models, 
as well as gain further insight into the features of the RS20 
region that are required for binding and activation of MLCK. 
rMLCK13 has the same amino acid composition, hydro- 
phobic  moment,  and  average hydrophobicity as  rMLCK1 
(Fig.  7 top), although the amino acid sequence within the 
RS20 region is inverted (Fig. 5). The proposed amphiphilic 
nature of the sequence is also maintained in the inverted se- 
quence (Fig.  7 top). rMLCK13 is not constitutively active 
and can be activated by calcium and CaM, although there is 
an increase in the concentration of CaM required for half- 
maximal activity (Fig. 7 bottom), which is reminiscent of the 
MLCK/CaMPK-II chimeric enzyme (rMLCK7). However, 
the response of rMLCK13 to mutant CaMs (Fig. 7 bottom) 
is much more diminished than that seen with rMLCK7 (Fig. 
6).  rMLKC13 still has the ability to discriminate between 
CaM and closely related proteins as evidenced by the inabil- 
ity to detect significant activity (>10 % of background) when 
caltractin is used in the assays instead of CaM. 
These data demonstrate that the orientation of the amino 
acid sequence, relative to the catalytic segment, is not a criti- 
cal feature of MLCK for proper recognition of CaM and re- 
lief of intramolecular inhibition, i.e., activation. The com- 
puted average hydrophobicity and hydrophobic moment of 
the sequences between residues 1,082-1,098  for the mutant 
MLCKs described in this and preceding sections also dem- 
onstrates that proper recognition and  functionally coupled 
binding of CaM  does not have a  simple relationship with 
these features, at least when function is assayed in the context 
of an active CaM-dependent enzyme. Overall, the fact that 
extensive alterations of  the sequence and the general features 
of the RS20 region does not produce a constitutively active, 
CaM-independent enzyme suggests that the autoinhibitory 
activity of MLCK may not be as critically dependent on the 
amino acid residues in the RS20 region as previously as- 
sumed based on model peptide studies. 
CaM Binding by MLCK Is Necessary but Not 
SuJSicient for Enzyme Activation 
All of  the mutant enzymes described in the preceding sections 
can be activated by CaM and calcium. However, rMLCK14 
and rMLCK15 (Fig.  5), generated by random mutagenesis 
of the RS20 region, bind CaM as judged by interaction with 
CaM-Sepharose columns and by gel overlay assays (Fig. 8), 
but cannot be activated by the calcium/CaM complex under 
these conditions. 
Altogether, the data for rMLCKs  1-15 demonstrate that 
the sequence requirements for CaM binding are less strict 
than those for CaM binding with resultant activation. Thus, 
while mutations in the RS20 region have not resulted in a 
constitutively active enzyme, it is possible for mutations in 
this region to functionally uncouple CaM binding from relief 
of autoinhibition. 
Removal of the AM13 and RS20 Regions 
Results in Constitutive Activity with Maintenance 
of  Substrate Specificity 
The ability to alter extensively the amino acid sequence of 
the RS20 region without generating a CaM-independent and 
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Figure  7.  CaM-dependent  MLCK 
activity is maintained  despite inver- 
sion of the CaM recognition region. 
(Top) The helical  wheel projections 
for rMLCK1 and rMLCKI3 demon- 
strate that the potential amphiphilic 
nature is maintained, but the relative 
orientation of the positively charged 
surface is altered.  Numbers  refer to 
the relative positions of these amino 
acid residues  in nmMLCK (Fig 2). 
rMLCK13 differs from rMLCK1 by 
the  inversion of the amino acid se- 
quence between  residues  1,082 and 
1,098 (see Fig. 5). However, the hy- 
drophobic moments (0.62) and aver- 
age hydrophobicity (-0.47) are iden- 
tical. Boxed residues denote charged 
amino  acids.  (Bottom) The  dose- 
dependent  activation  of rMLCK13 
by wild type (W.T) and mutant CaMs 
was tested as described in Materials 
and Methods. The mutant CaMs and 
relative  kinase  activity  calculations 
are the same as described  in Fig. 6. 
Error bars indicate the range of  values 
for the average of two experiments.  The CaM concentrations  indicated by the bars are 10 (crosshatched), 30 (left-directed diagonals), 
60 (horizontal), 260 (solid), 1,200 (open), and 4,000 nM (right-directed diagonals). 
constitutively active enzyme required a reexamination of au- 
toinhibition, and prompted an attempt to define more exactly 
the  boundaries  of the  CaM  regulatory  segment.  Previous 
studies (50) showed that a synthetic peptide analogue of the 
AM13  region (residues  1,068-1,080)  was a  competitive in- 
hibitor of MLCK activity, but did not have the high affinity 
CaM binding activity of RS20 analogues.  Therefore, as an 
initial  step  we  truncated  rMLCK1  immediately preceding 
the AM13  region by changing the codon for Ala-1068 to a 
translation termination codon. When this construct was ex- 
pressed in E. coil, a constitutively active enzyme (rMLCK16) 
was produced  (Fig.  9).  rMLCK16  did  not  bind  to  CaM- 
Sepharose  columns  and  did  not bind  CaM  in  gel  overlay 
assays. 
Although rMLCK16 has lost its ability to be autoinhibited 
and modulated by CaM,  it has maintained substrate spec- 
ificity.  The  apparent  Km  for  the  peptide  substrate  is  '~10 
/~M, similar to that for rMLCK1 or smMLCK (Table II) in 
the presence of CaM. These results demonstrate that autoin- 
hibition and CaM dependence of activation require the pres- 
ence of the AM13 and RS20 regions, but MLCK catalytic 
activity does not require the presence of these regions. Based 
on  these  results,  rMLCK16  is  an  excellent  candidate  for 
transfection studies that seek to overexpress a constitutively 
active protein  kinase  with  the  strict  substrate  recognition 
properties of an MLCK. 
Mutation of the AM13 Region Produces a 
Constitutively Active Enzyme That Binds CaM 
Overall, the results of the preceding sections demonstrate: 
(a) the importance of the AM13 and RS20 regions of MLCK 
in order to have an autoinhibited  enzyme that is activated 
selectively by CaM; (b) the requirement for a consensus se- 
quence in the RS20 region for proper CaM recognition and 
activation; and (c) the potential sensitivity of autoinhibition 
activity to the amino acid sequences  in the AM13  region. 
However, the suggested involvement of the AM13 region in 
Figure 8. CaM binding by MLCK is 
necessary  but not  sufficient for en- 
zyme activation, rMLCKI4 was pro- 
duced by random mutagenesis of the 
RS20  region,  binds  CaM  by  two 
criteria,  and cannot be activated by 
CaM  under  the  conditions  used. 
Lanes 1 and 2 are Western blots with 
anti-MLCK antibodies that demon- 
strate  the  binding  of rMLCK14  to 
CaM-Sepharose in a calcium-depen- 
dent manner, and lane 3 demonstrates 
CaM binding by a gel overlay tech- 
nique. Lane 1 contains proteins that 
did  not bind  to CaM-Sepharose  in 
the presence of calcium; lane 2 con- 
tains proteins that bound in the pres- 
ence  of calcium  and  eluted  with 
EGTA. The EGTA eluate containing 
rMLCK14  (lane  2)  also  binds  t25I- 
CaM in the presence  of calcium  as 
demonstrated by gel overlay (lane 3). 
rMLCK14  does  not  bind  ~25I-CaM 
in the presence of  EGTA (not shown). 
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deletion mutagenesis  results  that  removed more than  the 
AM13  sequence  (preceding section).  Therefore, we used 
substitution mutagenesis to explore how a perturbation of  the 
charge properties of the AM13 region would affect autoinhi- 
bition activity. As a starting point, we again used a cluster 
charge reversal mutagenesis approach (14,  80). 
In the charge reversal mutant rMLCK17, all of the posi- 
tively charged amino acid residues in the AM13 region have 
been changed to negatively charged glutamic acid residues 
(Fig.  5).  As summarized in Fig.  9,  rMLCK17 is constitu- 
tively active and binds CaM, but has little response to CaM. 
In fact, the ratio of activity for rMLCK17 in the presence or 
absence of CaM is similar to that observed with rMLCK16, 
which is a constitutively active deletion mutant. The ability 
of  the cluster mutation in the AM13 region to generate a con- 
stitutively active enzyme, however, was not observed in se- 
lected point charge reversals in this region, e.g., rMLCK18 
and rMLCK19 of Figs. 5 and 9. Similarly, combinations of 
selected point charge  reversals  in  the  AM13  region with 
point charge reversals in the RS20 region (e.g., rMLCK20 
of Fig. 5) did not result in a constitutively active enzyme or 
a suppressor mutant (data not shown). The ability of various 
multiple combinations of point charge reversals in the AM13 
region to produce constitutive activity was not tested as part 
of the study reported here. 
Altogether, these results and those from the preceding sec- 
tions demonstrate that the AM13 region is more important 
in autoinhibition than the RS20 region when the sequences 
are found in the context of an active, CaM-dependent en- 
zyme. Therefore, the CaM regulatory unit in a functional ki- 
nase would include, as a minimum, both the AM13 and RS20 
regions. Overall, the results suggest a segmental organiza- 
tion of functional units within MLCK that is more similar 
to CaMPK-II than previously thought. 
The topological similarities in the organization of the CaM 
regulatory segments  of MLCK and  CaMPK-II raised the 
possibility that their functional mechanisms could be simi- 
lar.  It  has  been  shown  that  autophosphorylation of Thr- 
286/287 during the activation of CaMPK-II results in a con- 
stitutively active enzyme (69). Further, when Thr-286/287 in 
CaMPK-II was changed to an ASp, CaMPK-II became con- 
stitutively active. Although autophosphorylation of MLCK 
has not been demonstrated, Thr-286/287 of CaMPK-II aligns 
with Ser 1072 in fibroblast MLCK (Fig. 3), and Ser-1072 is 
included in the autoinhibitory AM13 region of MLCK. To 
explore further the possible similarities in mechanism of ac- 
tivation for these two CaM regulated enzymes, Ser-1072 of 
MLCK was changed to Asp (production of rMLCK21, Fig. 
5). However, rMLCK21 is not constitutively active and re- 
quires  CaM  for activity (data not shown).  Therefore, the 
similarity in general segmental organization between MLCK 
and CaMPK-II cannot be extended to similarities in detailed 
mechanisms of activation, indicating the potential use of this 
mechanistic step for development of selective inhibitors. 
Summary Model and Activity 
A summary model of the chicken nmMLCK is shown in Fig. 
10.  Noted in Fig.  10 are the relative positions of selected 
regions implicated in function. There are several implica- 
tions of  this model based on the structure-function correlates 
presented here. For example, the ability of MLCK to with- 
Figure 9. Constitutively  active, 
CaM-independent MLCK ac- 
~  tivity results from removal or 
perturbation of  the autoinhibi- 
•  c  tory (AM13) region. Deletion  z 
"  of  the AM13 and RS20 regions 
0.~  by truncation of rMLCK1 at 
residue  1068 (production  of 
"  rMLCK16) results in a CaM- 
0.0  independent and constitutive- 
........  ly  active  MCLK.  A  cluster 
CALMODULIN  charge reversal  mutation with- 
in the AMI3 region (production of rMLCK17) also results in a con- 
stitutively active enzyme with little CaM dependence. The effects 
of  the cluster charge reversal were not mimicked by the point charge 
reversals in this region (rMLCK18, rMLCK19, and rMLCK20). 
The activation of these enzymes in the absence (- under horizontal 
bar) or presence (+ under solid bar) of I #M wild-type CaM was 
determined as described in Fig. 6. Error bars indicate the range of 
values for duplicate determinations. The changes in the amino acid 
sequence of rMLCK1 for these mutant MLCKs are summarized in 
Fig. 5. 
stand a number of changes and rearrangements within the 
CaM  recognition  region  suggests  that  mutations  or  in- 
dividual microheterogeneities within the MLCK gene en- 
coding  this  portion  of MLCK  may  not  result  in  drastic 
changes in the phenotype of an organism. This possibility, 
plus  the  apparent  selectivity  for  CaM  recognition  and 
MLCK autoinhibition by the CaM regulatory unit, make this 
region appealing as a potential target site for future develop- 
ment of selective antagonists, complementing the targeting 
of the active site/catalytic segment. 
The number of potential phosphorylation sites (Table I) 
within nmMLCK raises the possibility of significant regula- 
tory "cross-talk" between the CaM/MLCK signal transduc- 
tion pathway and several others involved in the regulation of 
cell proliferation and development. The ability of MLCK to 
withstand significant mutations within the RS20 region and 
to function without the presence of the KRP segment sug- 
gests the feasibility of mutating the amino acid sequence at 
certain phosphorylation sites, yet maintain function. Such 
mutant MLCKs might be useful in transfection experiments 
designed to probe the biological significance of phosphory- 
lation sites identified by in vitro studies, e.g., phosphoryla- 
tion sites at amino acids 1,100 and 1,113. Finally, the differ- 
ences in the proposed lengths of nmMLCK and smMLCK 
allow the potential design ofpeptides for production of selec- 
tive antibodies, or the design of selective nucleotide probes 
and antisense constructs. 
Treatment of CEF and 31"3 Cells with MLCK 
Antisense Oligodeoxynucleotides 
The availability of a cDNA sequence for a nmMLCK, and 
recombinant DNA constructs that encode either various seg- 
ments of  MLCK or constitutively active MLCK activity, pro- 
vide the opportunity to probe directly how MLCK and its 
segmental organization are related to in vivo activity. As a 
first step, we used synthetic oligodeoxynucleotides based on 
the cDNA sequence described here, to decrease the levels of 
MLCK and correlate the decrease with changes in cell mor- 
phology. Previous studies (75, 76) of MLCK levels in v-src- 
transformed CEF correlated a selective decrease in MLCK 
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Figure 10. Schematic model of nmMLCK segmental organization. A schematic summary of the amino acid sequence of chicken fibroblast 
MLCK (top line) is compared to two rMLCKs (rMLCK1 and rMLCKI6) and the sequence of chicken gizzard MLCK (smMLCK). As 
described in the text, these four protein kinases are indistinguishable in their catalytic properties, and three of the four (fibroblast MLCK, 
gizzard MLCK, and rMLCK1) are indistinguishable  in terms of their response to wild-type  and mutant CaMs. CaM recognition of rMLCK1 
can be altered by mutations in the RS20 region (Arg-l,082 to Met-l,101).  rMLCK1 can also be converted to a constitutively active enzyme 
with retention of CaM binding and substrate recognition activities by mutations in the AM13 region (Ala-l,068 to Met-l,080). Although 
Gly-811 and Arg-1047 are, respectively, the first and last conserved amino acids in the catalytic region as defined by the similarity analysis 
of Hanks et al. (24), the shortest sequence with full activity is rMLCK16 (Ala-519 to Glu-l,067), indicating that the minimal sequence 
for full MLCK activity has not been defined yet. Ala-l,102 represents the postulated start of the KRP/telokin sequence (Shattuck, R. L., 
and D. M. Watterson, unpublished data; 40), and the sequence equivalent to smMLCK starts at Met-286. The asterisks indicate the relative 
positions in the open reading frame used for the design of nmMLCK-selective and common antisense oligodeoxynucleotides. The two 
phosphorylation sites that have been identified (see Table I) are Ser-lll3 and Ser-ll00. The roman numerals (I, II, III) indicate the relative 
location of sequence motifs (see Fig. 4) found outside the catalytic and regulatory segments. 
activity, immunoreactive protein levels and  mRNA  levels 
with  the  altered,  more  rounded  morphology  and  growth 
properties  of  virally  transformed  cells.  However,  trans- 
formed cells have a number of biochemical changes, several 
of which may have a direct or indirect effect on cell morphol- 
ogy and components of the cytoskeleton. Therefore, we used 
the selective and more direct approach of antisense oligode- 
oxynucleotide treatment (34,  41)  in order to probe further 
5'  MLCK  sense 
5'  MLCK  antisense 
5'  MLCK mismatch 
3'  MLCK  sense 
3'  MLCK  antisense 
3'  MLCK mismatch 
5  v  v  3  w 
663  682 
AT  GGAT  GGAAGT  CAAGT  GAT 
AT  CAC  T  TGACTT  C  CAT  C  CAT 
AT  GAC  TAGACTT  G  C  TT  C  CAT 
3966  3985 
AT  GGCAAT  GAT  T  T  CT  GG  TAT 
ATACCAGAAAT  CAT  T  GC  CAT 
ATACACGAAATAC  T  TGC  CAT 
Figure 11.  Synthetic oligodeoxynucleo- 
tides based on the nmMLCK cDNA se- 
quence  and  used  in  antisense experi- 
ments.  The  sequences  of the  MLCK 
sense, antisense, and 4  base-mismatch 
oligodeoxynuclcotides are shown. Two 
regions of the eDNA sequence (Fig. 2) 
were used to design the antisense con- 
structs and controls: nucleotides 663- 
682 (5' MLCK) and nucleotides 3,966- 
3,985 (3' MLCK). As a control for each 
antisense, oligodeoxynucleotides corre- 
sponding to the "sense" sequence and a 
4  base-mismatch  antisense  sequence 
were made. Each of the sequences were 
compared with known DNA sequences 
in Genbank and EMBL databases and 
no alignments with more than 16 of 20 
matches were found. 
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MLCK levels. 
As shown in Fig.  11, two regions of the cDNA sequence 
of CEF MLCK were used to design the 20 base antisense 
oligodeoxynucleotides.  The  663-682  antisense  construct 
(5'-MLCK antisense) is targeted to an area of MLCK that is 
unique to nmMLCK, while the 3,966-3,985 antisense con- 
struct (3'-MLCK antisense) is targeted to a region that ap- 
pears to be common to nmMLCK, smMLCK and smooth 
muscle KRP. 
Treatment of CEF or 3T3 cells with the 5' or 3' MLCK an- 
tisense oligodeoxynucleotides  resulted in a striking morpho- 
logical change (Fig. 12). Both CEF and 3T3 cells exhibited 
a more rounded morphology, reminiscent of the morphologi- 
cal changes seen in v-src-transformed cells. The morpholog- 
ical change was time and dose dependent, with the majority 
of the cells showing a shape change after 16 h in the presence 
of 30 #M antisense oligodeoxynucleotide. In contrast, dose- 
dependent morphological changes were not seen in cells 
treated with the sense oligodeoxynucleotides, the mismatch 
oligodeoxynucleotides  or solvent (water) control. In parallel 
experiments, treatment of cells with MLCK antisense oligo- 
deoxynucleotides resulted in decreased levels  of immuno- 
reactive MLCK, as determined by Western blot analysis 
(Fig.  13). 
The effects of  the antisense oligodeoxynucleotides  are non- 
toxic and reversible. As illustrated in Fig.  12, there was a 
restoration of cellular morphology to the normal phenotype 
when  the  antisense  oligodeoxynucleotides were  removed 
from the cultures (by changing to a cell culture medium lack- 
ing oligodeoxynucleotide and allowing the cells to prolifer- 
ate for an additional 72 h). During recovery there was also 
an apparent increase in cell number and a return of MLCK 
activity to control levels.  Therefore, the lack of an effect of 
the various control treatments, and the reversibility of the 
effect of the antisense oligodeoxynucleotide  treatment, dem- 
onstrate that the effect on cell morphology is selective and 
nontoxic under these conditions. In addition to the reversible 
and nontoxic effect on morphology, there appears to be an 
effect of antisense oligodeoxynucleotides on cell prolifera- 
tion. For example, the cell densities in the control cultures 
were ~2.5-fold greater than those in the antisense-treated 
cultures after 40 h. These results raise the possibility of a 
role for nmMLCK in cell proliferation as well as cell mor- 
phology and motility. Altogether, these studies provide a di- 
rect link between changes in nonmuscle cell phenotype and 
MLCK activity, are consistent with conclusions drawn from 
previous  studies  (75)  of cells  transformed by  oncogenic 
viruses,  and provide  the  knowledge required  for a  more 
detailed analysis of  how the CaM/MLCK signal transduction 
pathway is coupled to and integrated with other signal trans- 
duction pathways in order to bring about cellular responses, 
and maintain cellular homeostasis in nonmuscle cells. 
Discussion 
The results described in this report provide insight into how 
the primary structure of a nmMLCK is related to the trans- 
duction  of  a  calcium  signal  into  a  biological  response 
through protein kinase activation, indicate a role for MLCK 
in nonmuscle cell homeostasis, and demonstrate a structural 
and possible genetic relationship between nmMLCK and 
smMLCK. Specifically, mapping of  the CaM regulatory unit 
within an active MLCK, and determining how the regions 
are related to selective recognition and activation by CaM, 
provided insight into how the CaM/MLCK complex is able 
to transduce a calcium signal into a biological response. In 
particular, the results are consistent with the model of Lukas 
et al. (48, 50), which suggests a segmental organization of 
the CaM regulatory region into distinct autoinhibitory and 
CaM binding elements, similar to the postulated segmental 
organization of CaMPK-II. Further, the ability of a charge 
reversal  mutation  (rMLCK2)  to  suppress  the  functional 
effects of charge reversal mutations in CaM provides con- 
vincing evidence that is consistent with the hypothesis (14, 
48, 50, 80) that complementary charge features of CaM and 
protein kinases are key to the formation and function of 
CaM/protein kinase signal transduction complexes.  On  a 
more general level, the functional effects of some of the mu- 
tations would not have been predicted based on precedents 
in structural biology and previous studies with peptide ana- 
logues and inhibitors.  Relatedly, the unique nature of the 
amino-terminal tall segment of the nmMLCK, combined 
with the presence of receptor-like motifs, raised interesting 
possibilities about the molecular basis of subcellular target- 
ing.  Overall,  the knowledge derived from the studies de- 
scribed here provide insight into, and a firm basis for dissect- 
ing how, an enzyme structure is related to nonmuscle cell 
structure and function, and how two mRNAs with extended 
sequence  identity  are  apparently  produced  in  a  tissue- 
selective manner. 
A primary goal of this study was to increase our under- 
standing of how MLCK selectively recognizes CaM  and 
which features of the CaM regulatory region are required for 
intramolecular  signal  transduction.  Chimeric  constructs, 
where the RS20 region (Fig.  5)  of fibroblast MLCK was 
replaced with the corresponding regions from skeletal mus- 
cle MLCK (rMLCK6) or CaMPK-II (rMLCK7), and site- 
specific mutagenesis within the RS20 sequence (rMLCK2- 
rMLCKI5) demonstrated the functional importance of the 
RS20 region in CaM recognition (Figs. 6, 8, and 9). Interest- 
ingly, while the RS20 region of MLCK is functionally coupled 
to the catalytic segment (intramolecular signal transduction 
between the CaM recognition and catalytic segments), the 
ability of the MLCKs mutated in the RS20 region to main- 
tain substrate specificity properties demonstrates the some- 
what autonomous or "cassette" nature of the segmentally 
organized primary structure. Similarly, the ability to exten- 
sively alter CaM recognition while maintaining autoinhibi- 
tion activity demonstrated the sequential nature of the pro- 
tein structure and function even within the CaM regulatory 
unit. In contrast, if the center of the autoinhibitory region 
was in the RS20 region, as has been proposed in many earlier 
models (discussed in the Introduction), then the mutagenesis 
of these residues would be expected, at least in some cases, 
to result in a constitutively active enzyme. 
The failure to demonstrate a constitutively active enzyme 
for any of  the mutations within the RS20 region, and the abil- 
ity of charge reversal mutations in the AM13 region to pro- 
duce a  constitutively active enzyme, demonstrate that the 
AM13  region  is  the  more  likely  candidate  for  critical 
residues involved in autoinhibition. Therefore, the models 
that are consistent with the results reported here are ones in 
which the CaM recognition and autoinhibitory sequences 
Shoemaker et al. Nonmuscle Myosin Light Chain Kinase  1121 Figure 12. Selective and reversible effects of antisense oligodeoxynucleotides on CEF and 3T3 cells. Treatment of CEF and 3T3 cells with 
sense or antisense  oligodeoxynucleotides  (shown in Fig.  11) for 16 h resulted  in a change in morphology with antisense,  but not sense, 
oligodeoxynucleotides.  Removal of antisense  oligodeoxynucleotides  by a change in media resulted  in a restoration to normal appearance 
as shown by the recovery after 72 h. Cells were plated at a density of "o104 cells/ml in a 24-well tissue culture plate (Falcon Labware, 
Oxnard, CA) and grown for 24 h in a-MEM (Gibco Laboratories, Grand Island, NY) containing 10% (vol/vol) fetal calf serum (HyClone 
Laboratories, Logan, UT). Medium was aspirated  at time zero, cells washed  with serum-free ct-MEM, and the oligodeoxynucleotides 
added (30/~M final concentration) in serum-free medium. After 2 h, serum was added to a final concentration of 2.5 % (vol/vol) and cells 
incubated at 37°C for 16 h (41). Cells were fixed with 2.5% (vol/vol) glutaraldehyde  and photographed. The effect of mismatch oligodeoxy- 
nucleotides or solvent  (water)  controls were indistinguishable  from the sense oligodeoxynucleotides shown. 
are distinct (39, 50), but intimately coupled in transducing 
the intramolecular signals that result in enzyme activation. 
The demonstration, in this report, that the nmMLCK and 
smMLCK  are  virtually  identical  within  the  catalytic  and 
CaM regulatory segments raises the reasonable question of 
why  a  recent  report  (4),  dealing  with  a  carboxy-terminal 
truncation mutation of smMLCK that appears to be equiva- 
lent to rMLCK16, was not able to show CaM-independent 
and constitutively active enzyme activity. We do not know 
the basis for these apparent differences,  although plausible 
explanations based on the results and model presented here 
are  available.  One  clear difference between  the  studies  of 
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MLCK antisense oligodeoxynucleotides for 
16 h results in a decrease in immunoreactive 
MLCK levels. After treatment of CEF with 
sense or antisense oligodeoxynuclcotides as 
described in Fig. 12, cells were harvested, 
lysed in sample buffer, and equal amounts 
of protein from each  sample analyzed by 
Western blot using a polyclonal anti-MLeK 
antiserum. A is the sample from cells treated 
with sense oligodeoxynucleotide and B is 
from antisense oligodeoxynucleotide treat- 
ment. Molecular weight standards (xl0  -3) 
are indicated on the right. 
Bagchi et al. (4) and ours is in the design aspects of protein 
engineering. The parental construct used here is rMLCK1, 
which is equivalent in length to skMLCK (Fig. 3), whereas 
the parental MK-40K construct of Bagchi et al. (4) is shorter 
than any naturally occurring MLCK. In addition, rMLCK1 
includes a set of sequence motifs from the amino-terminal 
tail segment that may be important in protein targeting or 
folding. The MK-40K construct lacks these amino-terminal 
structural motifs.  Relatedly, Herring et al.  (33) have been 
able to obtain CaM-dependent activity when they express a 
eDNA that encodes skMLCK, although they do not obtain 
activity if they truncate skMLCK at a position equivalent to 
amino acid 1077 of nmMLCK (Fig. 2, top).  From the per- 
spective of the model presented here, which is based on studies 
that include the analysis of sk/nmMLCK chimeras, the re- 
sults of Herring et al. (33) have alternative explanations. For 
example, the carboxy-terminal truncation mutation of Her- 
ring et al. (33) that lacks catalytic activity still contains 9 out 
of  the 13 amino acids in the segment of skMLCK that is simi- 
lar to AM13 (see Fig. 3). Clearly, this much of an AM13-1ike 
sequence might still function as an effective autoinhibitory 
region. In addition, this truncation of the skMLCK sequence 
also produces an MLCK that is shorter than naturally occur- 
ring MLCKs. These earlier reports also raise the possibility 
that the exact sequence at the carboxy-terminal end of a con- 
struct might affect protein folding. In this regard, our mutant 
MLCKs that were truncated within the AM13 region were 
less amenable to purification and characterization than those 
shown in Fig. 5 (unpublished observation). Overall, the model 
presented here for how the segmental structural organization 
of MLCK is related to function is not only consistent with 
the results presented here, it is consistent with other results 
that cannot be adequately explained by autoinhibition models 
that equate CaM binding sequences with autoinhibitory se- 
quences. 
Of the 20 mutations of rMLCK1 that were made and ana- 
lyzed as part of this study, at least two provided novel results 
that have implications beyond the area of intracellular cal- 
cium signal transduction. These mutants are rMLCK2 and 
rMLCK13. The suppressor mutant rMLCK2 was  designed 
based on previous studies which demonstrated that: (a) the 
RS20 region has selective, high affinity CaM binding activity 
(48,  50); and (b) protein electrostatics might be important 
in protein recognition and calcium signal transduction by 
CaM:protein kinase complexes (14,  80). The production of 
this desired suppressor mutation at a protein/protein interac- 
tion region was based on considerations of structure, mecha- 
nism,  and  thermodynamics,  not on  random mutagenesis, 
screening,  and phenotypic selection.  Therefore, rMLCK2 
has interesting features in terms of the approaches used in 
its design, and in terms of its potential for providing insight 
into how an enzyme activity can be modulated by an effector 
protein.  However, it should be noted that the results with 
rMLCK2 do not require that the residues within the Arg- 
Arg-Lys sequence be involved in intermolecular contacts be- 
tween CaM and MLCK, but they also do not preclude the 
possibility.  Knowledge about the three-dimensional struc- 
ture of a series of wild-type and mutant protein complexes 
is needed in order to understand how functional suppression 
is related to the structure of the complex. 
The maintenance of function in rMLCK13, which has an 
inverted amino acid sequence, was both unexpected and re- 
vealing in terms of regulatory mechanism and protein recog- 
nition. We are not aware of a similar case where a functional 
unit in a protein has been inverted in sequence orientation 
with  maintenance  of function,  although  these  results  are 
reminiscent of the aspects of symmetry observed in DNA/ 
protein recognition. Although there appears to be a lack of 
precedents for rMLCK13 in terms of  protein/protein interac- 
tion, the peptide analogue studies of  fibronectin (83) are rele- 
vant, although different in result.  In this system, synthetic 
peptide analogues of a tetrapeptide cell adhesion region of 
fibronectin were made in reverse order with a maintenance 
of activity when the sequence was a short peptide. However, 
when the inverted sequence was placed into the context of 
a  larger peptide,  more like its  environment when the se- 
quence is resident in the protein, the inverted sequence was 
inactive. In contrast, when the CaM recognition sequence 
was  inverted in MLCK (rMLCK13), CaM recognition and 
intramolecular signal transduction functions were maintained, 
as evidenced by the selective recognition of CaM and resul- 
tant relief of intramolecular inhibition (Fig.  7). 
Overall, the ability of the CaM/MLCK complex to com- 
pensate functionally for extensive alterations in the CaM rec- 
ognition region indicates that mutations within the exons en- 
coding this region would not necessarily be lethal or always 
result in a major phenotypic change. In this regard, the mo- 
lecular genetics and phenotypic manifestations of inherited 
alterations in the CaM/MLCK complex might have thematic 
similarities to CaM regulated ion channels, where inherited 
mutations of CaM must be strong enough to detect, but weak 
enough not to be lethal (51). The results of  antisense oligode- 
oxynucleotide studies described in this report demonstrate 
that  transient decreases  in  MLCK  levels can bring about 
phenotypic changes that are nonlethal. However, it is possi- 
ble that pathological states could result if these changes in 
nonmuscle cell MLCK activity are combined with changes 
that normally occur during development and differentiation, 
or if these changes in  MLCK activity are combined with 
changes in other protein kinases or phosphatases that occur 
during physiological responses or cell cycle progression. Al- 
together, the information, tools and insights derived from 
this study provide a firm and more rational basis for the de- 
sign and interpretation of physiological and genetic studies 
that seek to explore these possibilities. 
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